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ABSTRACT 
Epigenetic modifications, at the level of DNA methylation and post-translational modifications of histone tails 
cooperatively function in the organization of the genome, and thereby establish the gene expression profiles, 
phenotypes, and cellular fates.  In this work, we investigated the aberrant epigenome in chronic lymphocytic 
leukemia (CLL) which is one of the most frequent lymphoid malignancies in the west including the Nordic 
countries. The overall aim of this work is to address the impact of altered epigenetic patterns in CLL on the 
disease progression with respect to gene expression profile and gain mechanistic insights on the interplay 
between the different epigenetic mechanisms, such as DNA methylation and histone modifications, in 
regulating the expression of CLL signature genes. The first study in this thesis aims to investigate the impact 
of gene body hypermethylation on transcriptional activation which was not completely understood then. 
Based on our previous MBD seq data (Methyl-CpG-Binding Domain based next generation Sequencing) 
datasets on CLL samples, of the top differentially methylated genes in CLL compared to normal B cells, we 
nominated Ten-eleven translocation (TET1) which was shown to harbor hypermethylation at CpG islands 
within gene body. We found that gene body of TET1 harbors an overlapping cryptic promoter, the transcript 
of which attenuates the corresponding gene transcription when unmethylated and its hypermethylation in CLL 
was found to be associated with the overexpression of TET1. The second study aimed at globally mapping the 
genomic targets of enhancer of zeste homolog 2 (EZH2) the catalytic subunit of Polycomb repressive complex 
2 (PRC2) in CLL by chromatin immunoprecipitation followed by sequencing (ChIP-seq) along with its 
prototypical repressive chromatin feature (H3K27me3). The findings of this study unraveled a non-canonical 
implication of EZH2 in transcriptional activation apart from PRC2. We show a mechanism by which EZH2 
transactivates IGF1R gene in the more adverse CLL subgroups with IGHV mutations (mutated CLL) and how 
it contributes to activating PI3K/AKT pathway through IGF1R signaling. The third project is somehow 
pertinent to the aforementioned first study and aims at drawing a more detailed mechanistic link between CpG 
methylation and transcriptional regulation in terms of the residence of PRC2, as it preferentially locates GC-
rich elements. Integration of our previous global methylome datasets in CLL patients and transcriptome 
analysis by RNA-seq after induction of global demethylation in CLL cell lines has revealed a set of genes that 
are supposedly prone to hypermethylation within their intragenic regions in CLL, and such hypermethyation is 
found to be positively correlated with their overexpression in CLL. Out of the top significant genes, MNX1 
was selected to probe the mutual exclusivity of PRC2 and intragenic CpG islands and the possible implication 
of gene body hypermethylation in upregulating MNX1 in CLL through impeding the PRC2-mediated 
 repression.  Altogether, the findings of our work underscore that aberrant epigenome is more likely to be the 
niche within which the cancer type-relevant aggressive traits are acquired and might pave the way for further 
detailed investigations that look forward to improve the therapy options and accordingly the clinical outcomes 
in CLL. 
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SAMMANFATTNING PÅ SVENSKA 
Förändringar i arvsmassan som leder till ändrat uttryck av gener utan att DNA-sekvensen ändras kallas 
epigenetik och inkluderar metylering av DNA och post-translationella modifieringar av histonernas svansar. 
Dessa samverkar med varandra och kan leda till ändrat genuttryck och därigenom också en ändrad fenotyp 
hos celler, utan att DNA-sekvensen påverkats. I denna studie undersökte vi det avvikande epigenetiska 
mönster som ses vid kronisk lymfocytisk leukemi (KLL), som är den vanligaste lymfoida neoplasi i 
västvärlden inklusive de nordiska länderna. Det övergripande syftet med denna studie är att avgöra betydelsen 
av dessa epigenetiska förändringar och deras relation till förändrat genuttryck och sjukdomsprogress som ses 
vid KLL samt förstå samspelet mellan olika epigenetiska mekanismer, så som DNA-metylering och 
modifieringar av histoner, och genuttryck.  
Den första studien syftade till att undersöka hypermetylerings betydelse vid aktivering av genen Ten eleven 
translocation 1 (TET1), där våra tidigare resultat från kartläggning av den globala DNA-metylering vid KLL 
visat att genen var differentiellt metylerad vid jämförelse mellan KLL-celler och normala B-celler. Genen för 
TET1 visade sig ha en överlappande kryptisk promotor, vars transkript dämpar transkriptionen av TET1 när 
den inte är metylerad.  
Den andra studien syftade till att globalt kartlägga vilka gener som Enhancer of zeste homolg 2 (EZH2), den 
katalytisk enheten i polycomb repressive complex 2 (PRC2), reglerar genom att analysera väl karakteriserade 
KLL prover genom användning av kromatin-immunprecipitering riktade mot H3K27me3, följt av 
sekvensering (s.k. ChIP-seq). På detta sätt identifierade vi en PCR2 oberoende icke-kanonisk funktion hos 
EZH2 vid transkriptionell aktivering. Sammantaget visar våra resultat att EZH2 transaktiverar IGF1R-genen 
vilket bidrar till aktivering av PI3K / AKT-signalvägen i den prognostiskt mer ogynnsamma subgruppen av 
KLL. 
Vårt tredje projekt syftade till att ge en mer detaljerad mekanistisk förklaring mellan CpG-metylering och 
transkriptionell reglering av MNX1-genen och dess roll för bindning av PRC2 till GC-rika element och 
aktivering av promotorer. 
KLL är en obotlig sjukdom men med mycket varierande kliniskt förlopp. Ökad förståelse för de epigenetiska 
förändringarna som ligger bakom en mer ogynnsam sjukdomsprogression kan bana väg för utveckling av mer 
riktade behandlingsstrategier med avsikt att reversera dessa förändringar för att förbättra de kliniska resultaten 
vid KLL.
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1 INTRODUCTION 
 
The rise of high throughput and massively parallel technologies has revolutionized the field of 
genomics and epigenomics. This revolution has in turn enhanced understanding of genome 
organization and the mechanisms orchestrating the interplay between the genome and epigenome 
towards driving both normal and diseased phenotypes. 
The emergence of regulatory genomic elements and the expansion of the haploid genome size in 
higher organisms entail highly sophisticated mechanisms, so that they govern and regulate the 
genome function in establishing gene expression profiles in response to either normal cellular 
conditions or stochastic environmental circumstances. Along with the sequence-based intrinsic 
features of the genomic domains, epigenetic mechanisms serve an integral part in this regard 
without altering the genomic sequences. Epigenetic mechanisms involve chemical modification of 
DNA bases such as cytosine methylation and histone post-translational modifications, which in 
harmony with long non-coding RNAs (LncRNAs) organize the eukaryotic, particularly the 
mammalian genome into functionally distinct compartments, thereby control gene expression in a 
spatial and temporal manner.  
Alterations that encounter any of these mechanisms have extensively been reported in many 
diseases including cancer. Aberrant epigenetic patterns have been shown to adopt the mutational 
load and encompass many notorious cytogenetic lesions that arise with the progression of 
malignant diseases, suggesting that cancer is more than a disease of mutations. Altered DNA 
methylation has been well addressed in cancers and viewed to cooperate with abnormal histone 
modification pattern to foster the acquisition of the malignant hallmarks. 
By means of high through-put sequencing techniques and with integration of current along with 
previously published global datasets by our team, this work mainly aims at identification of the 
altered epigenome in terms of DNA methylation and polycomb repressive complex 2 (PRC2) 
deregulation in chronic lymphocytic leukemia (CLL). In addition, we aimed at dissecting the 
crosstalk between these epigenetic mechanisms in reprogramming and altering gene expression. 
More specifically, the main concern of this work is drawing more detailed mechanistic links 
between DNA methylation and PRC2 in regulating sets of  biologically relevant genes that are 
related to the proliferative pathways such as IGF1R signaling, PI3K/AKT pathway as well as 
homeobox-related genes and how that contributes to CLL pathogenesis.  
Comprehensive understanding of the altered aspects of epigenetic mechanisms in CLL and other 
cancers in general, along with translational medicine may pave the way for improving and 
elaborating promising and more efficient lines of therapy and improve the patients’ prognosis. 
1.1 Genome: The pivotal dimensions of complexity in normal 
development and diseases 
1.1.1 Genome and complexity of living organisms 
 
The last two decades following the completion of Human Genome and ENCODE projects, have 
witnessed a stunning paradigm shift. It was previously believed that the living organisms are 
hard-wired by their genes, as implied by the central dogma of molecular biology.[1] The central 
dogma defines life or a biological phenomenon as a flow of genetic information embedded in the 
DNA into a messenger RNA (mRNA), which is in turn translated into a biologically functional 
protein that contributes to manifestation of phenotypes.  
Throughout the evolution of the living organisms, a wide range of biological diversity and 
scalable broad spectrum of organismal complexities are observed from symbiotic bacteria to 
humans.[2]  The intriguing question is that, what stands behind and what confers such diverse 
biological complexities?  
It was believed until the early 1970s of the last century that the organismal complexity is scaled 
by the cellular contents of DNA (the C-value).[3] The notion that the C-value failed to show a 
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significantly consistent relationship to biological complexity raised the C-value paradox.[2, 4-7] 
The C-value paradox was rationally resolved by the fact that the C-value is not more than a crude 
measure of cellular DNA content and is not normalized to varying degrees of ploidy and the 
emergence of non-protein coding elements into the genomes of higher organisms.[8, 9]  
Another intriguing paradox in molecular biology is the inconsistent relationship between 
developmental complexity and the number of protein-coding genes, referred to as the G-value 
paradox.[10] According to the central dogma, one would expect that the organismal complexity is 
supposedly scaled up by the increase of the protein-coding sequences. However, one striking 
example amidst myriads, has casted a remarkable skepticism on this tenet; the mean number of 
protein-coding genes in human and in the microscopic nematode C.elegans is 20,000 genes.[2] 
Moreover, the human genome project revealed that the sequences of DNA that are synonymous 
with functional proteins represent less than 2% of the whole haploid genome, while the rest was 
termed as “Junk DNA” or “Selfish DNA”.[8, 9] After the revolution in the field of genomics, the 
Junk DNA turned out to be biologically relevant to the development of the higher organisms. This 
98% of the human genome is broadly partitioned into cis-acting regulatory elements and non-
protein-coding sequence that are not inert and code for trans-acting non-coding RNAs (ncRNAs), 
which in turn fulfil a broad spectrum of cellular and developmental functions. Together, these 
elements cooperatively contribute to the establishment of the highly sophisticated architecture and 
dynamic organization of the genome, and thus control gene expression in a spatial and temporal 
manner and account for the gene product diversity throughout the multicellular ontogeny.[2]  
The non-random overrepresentation of non-genic elements including introns and intergenic 
elements would evoke our thinking of the mechanisms beyond the intrinsic sequence properties 
and the information stored in our genomes, and how these mechanisms shape our genomes and 
accordingly control the flow of genetic information towards a stable phenotype.[2, 11] These 
mechanisms are known as epigenetic mechanisms which control, influence and get influenced by 
the genome without altering the DNA sequence, and thus account for cellular memory upon 
reaching the terminal stage of differentiation.[12]  
By virtue of next generation sequencing and massively-parallel technologies, our comprehension 
of biological and physiological processes and the development of diseases such as cancer, has 
experienced a transition from a gene-centered to a genome-wide approach. Also, as best 
expressed by Adrian Bird[12], the revolution in the field of epigenetics has offered an antidote to 
the tenet that a living organism is equal to the summation of its genes; an organism is rather a 
function of its genome. 
1.1.2 The problem of cancer  
 
During the multistep process of cancer development from normal cellular incipient, new 
biological capabilities are acquired, following the cumulative disruptions to normal growth 
controls. These new traits comprise the hallmarks of cancer and confer the survival and 
aggressiveness of cancer through providing the greatest clonal advantages, that in turn qualify the 
progression of the neoplastic cells that are ultimately becoming malignant tumor.[13] These 
hallmarks were first introduced in the year 2000 by Douglas Hanahan and Robert 
A.Weinberg.[14] This proposition constituted an organizing principle and a conceptual 
framework for understanding the diversity and complexity of human neoplasms.[15]  
These hallmarks include six biological traits:  
1. Sustainable proliferative 
signaling 
2. Evading growth suppressors 
3. Resistance to cellular death 
 
 
 
 
4. Enabling replicative immor-
tality 
5. Induction of angiogenesis 
6. Activation of invasion and 
metastasis 
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A decade later and with the conceptual progress and accumulation of a wealth of knowledge, 
Douglas and Weinberg introduced an ancillary proposition which implied additional two hallmark 
traits. Reprogramming of energy metabolism and evasion of immune-mediated destruction are 
two emerging capabilities have been added to the list of cancer hallmarks. 
The fairly intriguing question is: what underlies the acquisition, preservation and fostering of 
these traits? And which physiological niche would embrace the clonal selection of the 
competent neoplastic cells?  
Genomic instabilities and inflammation underlie these hallmarks through generating genetic 
diversity, thereby expedite their acquisition and foster their functions. Both are considered as 
enabling characteristics that account for the Darwinian selection of these new traits, thus provide 
the greatest clonal advantages for survival and generation of macroscopic tumors. The dimensions 
of complexity of cancers is superimposed by their ability to recruit apparently normal cells that 
help in establishing the so called tumor microenvironment which constitutes as a physiological 
niche encompassing the acquisition and contribution of the hallmarks traits in tumor 
progression.[16, 17]   
Throughout the course of tumorigenesis, the cells destined to become malignant experience suc-
cessions of drastic conditions elicited by the natural barriers which are hard wired into the cells to 
impede outgrowth of either pre-neoplasms or frank neoplastic lesions and functions in various 
combinations of tumor suppressive modes of action.[15] Neoplastic cells relentlessly invest the 
malignant capabilities they have been acquiring to circumvent such anticancer defense activities. 
Therefore, the developing neoplastic cells can overcome such bottle neck by compromising the 
gene expression profile (GEP) for the tumor advantage.[18, 19]  
By means of epigenetic mechanisms, the expression of the components of surveillance system 
that ensure genetic and genomic integrity is altered [20-22]. Most importantly gate-keepers and 
care-takers that evoke genomic maintenance and DNA repair or otherwise trigger senescence 
and/or apoptosis of genetically damaged cells are compromised; thereby cancer increases the 
mutational load and guarantees the accumulation of genetic aberration and cytogenetic lesions 
that are well suited as vehicles of persistent phenotypical oncogenic changes and candidates for 
clonal selection. 
The dynamic reprogramming of gene expression profile and the shaping of malignant phenotype 
is a culminate result of cooperative integration between altered genetic and epigenetic 
mechanisms like methylation of DNA or post-translational modification of histones that foster 
acquisition of hallmark traits.[13, 23, 24] Here comes the significance of epigenetic mechanism in 
providing alternative and flexible, yet persistent ways to regulate and acquire stable oncogenic 
traits throughout multiple cellular division cycles that would potentially boost the neoplastic 
phenotypes.[25]  
 
1.1.3 Cancer epigenome 
 
During the last century, cancer has generally been viewed as a genetic disease; the general tenet 
that was adopted then implied that mutations are the driving forces that initiate the neoplastic 
transformation.[13] However, it has become clear that rate of mutations, copy number alterations 
and insertion/deletions take place at relatively low frequencies; thus rendering them inefficient 
means of initially driving neoplastic transformation. 
Considering the local influence of base composition on single nucleotide variation (SNV), 
chromatin structure, replication timing and regional effects of sequence composition and mutation 
rates across the genome vary markedly.[26] Notably, the mutational load in cancer can by no 
means be inferred directly from the number or frequency of observed mutations, without taking 
the number of cell divisions that have occurred or the influence of epigenetic mechanism on the 
rate of generation and repair of such altered genetic lesions into account. 
Epigenetic mechanisms have an influential role in mutational rate in several ways. Most 
importantly, certain subsets of colorectal cancers and glioblastomas show epigenetically-addictive 
phenotypes, wherein the incipient pre-neoplastic cells exhibit a predisposition towards 
Genome-wide epigenetic profiling of B cell leukemia and lymphoma 
4 
exceptionally high frequency of cytosine methylation at CpG-rich promoter of certain genes the 
silencing of which is of a molecular and biological relevance to the respective malignancies. This 
phenomenon is referred to as CpG island methylator phenotype (CIMP) [27, 28], where the 
exceeding frequency of promoter methylation is neither stochastic nor spontaneous, but instead an 
epigenetically attributed and highly coordinated event. Such predisposition towards epigenetic 
addicted phenotypes may be a consequence of germline variation that increases the likelihood of 
cancer development.[29, 30] Another facet of epigenetic addition is exhibited in aberrant 
chromatin organization that is attributed to gain-of function of chromatin modifiers as evident in 
Polycomb repressive complex addiction in diffuse large B cell lymphoma (DLBCL) [31-33] and 
DOT1L-addiction in subsets of mixed lineage leukemia (MLL) which is associated to altered 
regulation of Homoebox-related genes.[34-36]    
Also, cytosine methylation in the context of CIMP has been shown to play a crucial role in the 
boosting the rate of C-to-T mutation within CpG islands up to tens of folds of magnitudes.[26] 
The C-to-T mutations during DNA replication in highly proliferative cells result in T:A 
substitution lesion which are not recognized by the DNA repair machinery. These kind 
epigenetically-attributed mutations constitute about 25% of all TP53 mutations in human 
cancers.[37]  
Altogether, the aforementioned facts support the contribution of epigenetics to cancer mutational 
load and that epigenetic alterations might act upstream to foster the acquisition of the cytogenetic 
lesions throughout the course of tumorigenesis and maintain them to boost the malignant 
phenotypes and achieve the best clonal traits.[13, 38]  
It has become evident that both genome and epigenome influence each other as a mean of high-
fidelity and tight control of gene expression profile and fate specification. The next chapter 
explains the different epigenetic mechanisms at the levels both DNA and histone modification, 
the regulation of epigenetic marks at the levels of writing and erasure, and the interaction between 
the different epigenetic patterns and show that they are not operating in isolation, but rather within 
a an integrative network of mutually exclusive, reinforcing and  counteracting signals. 
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1.2 Epigenetics: the flexible mediators of genome dynamicity 
1.2.1 Epigenetics at a glance 
 
The term “Epigenetics” was first coined in 1939 by Conrad Hal Waddington, nevertheless, so 
many definitions have been suggested for epigenetics thereafter.[12] According to Waddington, 
and apart from classical genetics, epigenetics concerns about how genotypes manifest phenotypes. 
In his own words, epigenetics is defined as “the branch of biology which studies the causal 
interactions between genes and their products, which bring the phenotype into being”.[39, 40]  
The definition of epigenetics remained subject of debate, until the mid-1970s, when the field of 
epigenetics was revived once again by Arthur Riggs and coworkers.[41] They could reformulate 
the definition and reintroduce the biological importance of epigenetics, so that the term refers to 
the study of mitotically and/or meiotically heritable changes in genetic functions beyond sequence 
alteration of DNA itself. More specifically, epigenetics describes the interplay between the 
reversible chemical modifications of histone tails and/or DNA without changing the genetic 
information, and chromatin-associated proteins, in regulating chromatin structure and 
transcriptional programs of the cells.[42]  
In brief, epigenetics is inheritance, but not as we know. It is suggested to be described as “the 
soul” of the genome that organizes its function in response to the environmental conditions or 
developmental demands, thereby coins the cellular identity and guarantees the phenotypic 
distinctiveness of each type of the genetically identical cells that comprise a multicellular 
organism. 
 
1.2.2 Epigenetics: what stands behind genome’s function? 
 
The succession of the technological advances in the post-sequencing era and the rise of the high 
throughput technologies have revolutionized the field of epigenetics and offered several genome-
wide-based lines of investigations. By virtue of such technological revolution, the functions and 
distribution of several epigenetic marks over the genome have been accurately mapped and 
comprehensively understood. The different epigenetic modifications at the levels of DNA and 
histones modification are considered as surrogates of the functional genomic elements, structural 
organization of chromatin domains and transcriptional potentials across the chromatin 
domains.[43]  
As explained in section1.1, the evolution of the higher organisms had experienced genomic size 
expansion, as a consequence of the emergence of non-protein-coding elements including 
repetitive elements which are mainly transposons-derived, intergenic regulatory elements and 
intragenic introns. This latter set of elements largely accounts for the expansion of eukaryotic 
proteomes by alternative splicing.[44] Such complexity of the eukaryotic genomes, in particular 
the mammalian genomes, entails highly sophisticated patterns of organization, that aim at not 
only structural packaging of the genome within the nuclear vicinity, but also functional arraying 
of the genomic elements and delineating the distinct chromatin domains. The mammalian genome 
is viewed as a series of superimposed organizational layers rooted in the double stranded DNA 
(dsDNA).[13, 45, 46] Approximately 147 bp of DNA is wrapped twice around histone octamer 
that is composed of dimers of H2A, H2B, H3 and H4 core histones, comprising a nucleosome, the 
building unit of chromatin.[47-49]  
The chromatin is compartmentalized into structurally and functionally distinct domains that are 
established and demarcated by epigenetic modifications. These domains are principally classified 
into euchromatin regions, the conformation of which is accessible to the transcriptional 
machinery, and heterochromatin, which is on the contrary, closed and is transcriptionally 
inactive.[50] This latter is further classified based on several factors, most importantly the 
intrinsic sequence-based criteria and their replicative timing of the genomic sequences that 
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comprise these domains, into facultative heterochromatin and constitutive heterochromatin.[51-
53]   
This organization is highly context-dependent, in the sense that chromatin is not static, but rather 
dynamically varies across the cellular conditions, either during development and lineage 
specification, or upon cellular reprogramming and neoplastic transformation.[13, 43] Also, the 
higher order of chromatin organization is cell-type specific and is established by interplay 
between the genomic features and epigenetic machinery. Thus, epigenetic patterns elicit a 
“memory” for the cell, that they mediate and implement the decisions that has been taken by the 
cell during development from totipotent towards its terminally differentiated state, through 
shaping the gene expression profile of the cell and manifesting the unique phenotype. Perhaps, the 
key fundamental facet of epigenetic patterns is that they themselves are faithfully maintained 
throughout the successive cell division cycles, and in turn reciprocate by stabilizing the phenotype 
of the terminally differentiated cell and maintaining its identity.[54] Accordingly, the cellular 
epigenome seems more likely to be the “mind” of the cell.  
1.2.3 Epigenetic patterns establishment 
 
Establishing the epigenome demands reversible chemical modification either at the DNA level; 
most famously, DNA methylation which is achieved by adding methyl group on the fifth carbon 
atom of cytosine bases forming 5-methyl cytosine (5-mC), or by post translational modification of 
histone proteins by acetylation, phosphorylation, sumoylation, ubiquitinylation or most 
prominently methylation. Such chemical modifications are referred to as “epigenetic marks”. 
These marks are either surrogates of open chromatin structures and active transcription, or 
prototypes of closed conformation and diminished transcriptional potential. Each of these marks 
is regulated by counterbalancing activities of “writers” and “erasers”. The writers catalyze the 
establishment of the chemical modification at DNA or histones levels, while the erasers catalyze 
the removal of the epigenetic mark.[55] For example, a histone lysine methylation mark is 
catalyzed by a dedicated histone methyl transferase and erased by a demethylase. The balance 
between writers and erasers is tightly controlled based on the cellular conditions and 
developmental needs. As pointed out above, epigenetic patterns are not insulated from each other 
and they are operating within an integrative network governed by a collaboration of multiple 
regulatory mediators including: 
1. Readers: Readers are proteins with featured domains by which they recognize 
specific epigenetic marks. These domains include PHD fingers, WD40, Ankyrin, 
PWWP, MBT, Chromodomains, Tudor domains and others.[55] Upon recognizing a 
certain epigenetic feature, readers can either convey signals to downstream effectors 
that implement a dedicated epigenetic function in establishing local chromatin 
structure (e.g. ATP-dependent chromatin remodelers), or recruit other epigenetic 
regulators and moderate the crosstalk between the mutually reinforcing epigenetic 
machineries. Also, some readers of certain epigenetic marks function as erasers of 
another antagonizing epigenetic feature. For example, PHF8 reads the active mark 
H3K4me3 via its PHD domain in the euchromatic contexts, and under certain 
circumstances it serves in erasure of the repressive H3K27me3 mark from the same 
context by its Jumonji C (JmjC) domain.[56, 57] 
2. Long non-coding RNAs (LncRNAs): LncRNAs are also known as “initiators” that 
serve in recognizing the chromatin status in terms of conformation and 
transcriptional activity and recruiting the epigenetic machineries to their targets in a 
spatial and temporal manner. Many lncRNAs have been shown to recruit polycomb 
repressive complex 2 (PRC2) to their targets over the genome.[58-61]     
3. Genomic sequence: DNA sequences in part, play a role for directing and shaping 
epigenetic patterns. Among several examples, DNA methylation is highly dependent 
on and influenced by the genomic context. For instance, CpG islands (CGIs) are by 
default unmethylated and are rendered protected from methylation, in spite of the 
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methylation attrition, by several factors, most prominently, the strand asymmetry at 
the GC-rich regions which is in turn associated with R-loop formation.[62] 
On the other hand, CpG dinucleotides in the context of CpG oceans are more prone 
to methylation, as explained in details below (section1.2.4).[63-65] It is also 
noteworthy that the functionally distinct chromatin domains that are studded by 
counteracting epigenetic marks are delineated, in a way that prevents the spreading 
of the repressive regions or the firing of unintended promoters or enhancers 
activities. This is mainly accomplished by the binding of CTCF proteins to insulator 
elements, so that the different chromatin domains are stably demarcated.[66-68]         
4. Nucleosome positioning and turnover: Nucleosome turnover has been suggested to 
play a role in regulating the pattern of histone methylation, in terms of influencing 
the processive kinetics of the corresponding histone methyl transferases and the 
valence of methylation mark on histone lysine residues. For instance H3K79 
methylation is known to be written by DOT1L, while no dedicated eraser has been 
characterized so far. Recently, it was found that the rate of nucleosomal turnover 
preferentially associate with the lower states of H3K79 methylation valence and in 
turn influence the dynamicity of the local chromatin and its transcriptional potential 
as well.[69] Also, it was shown that the rate of nucleosomal turnover affect the 
inheritance of repressive chromatin regions that are marked by H3K9me3, in a way 
that entails suppression of the turnover rates by SMARCAD1 of the SNF2 family 
proteins to faithfully maintain the transmission of such epigenetic feature to the 
progeny cell.[70] In brief, the rate of nucleosome turnover is likely to be negatively 
correlated with suppressive epigenetic features, while directly proportional to active 
chromatin marks.  
5. DNA replication timing: The maintenance and faithful copying of epigenetic 
patterns is influenced by the replication timing, in the sense that the epigenetic 
features on the early replicated regions are rapidly restored on the daughter DNA 
strand compared to the late replicating regions that are mainly decorated with 
repressive chromatin marks like H3K9/27 methylation which might take longer time 
that exceeds the time of the cell division, so that the restoration completes after the 
entry into G1 phase of the next cycle.[54, 71-73] 
 
1.2.4 DNA methylation 
 
DNA methylation has been viewed as an epigenetic prototype of transcriptional silencing that 
characterizes long-term stable repression.[74] In contrast to histone modification, DNA 
methylation is less dynamic and not easily reversed, consistent to its implication in long-range 
silencing that is most evident in X-chromosome inactivation and genomic imprinting.[75, 76]  
Methylation of cytosine bases within the genomic DNA is the most prominent methylation mark 
that has been a matter of deep interrogation, and the succession of the findings that have come out 
since the mid-1970s raised remarkable debate regarding the relationship between DNA 
methylation and transcriptional silencing.[41, 77] 
To accurately describe the functional link between DNA methylation and transcriptional 
regulation, the distribution of methylation across the different genomic elements and its location 
within the transcriptional unit should be considered.[64, 74, 78] DNA methylation takes place to 
modify either Cytosine or Guanine residues yielding 5-methyl Cytosine (5-mC or O6-methyl 
Guanine, respectively.[79, 80] 
I hereby in this thesis focus on the methylation at cytosine and its implication in establishing 
chromatin structure and regulation of gene expression. 
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DNA methylation machinery: Writing, reading and erasing 
 
The deposition of a methyl group at the fifth carbon atom of cytosine bases is catalyzed by a set 
of evolutionarily conserved DNA methyl transferases (DNMTs).[81, 82] More tellingly, the DNA 
methylation patterns are established de novo during the early embryonic stages by DNMT3A, 
DNMT3B, and a non-catalytic DNMT3L, the function of which is to recognize chromatin status 
in terms of histone modification (discussed below) and accordingly direct the de novo methyl 
transferases DNMT3A/B to the target genomic sequence.[83, 84] On the other hand, the 
maintenance of DNA methylation is carried out principally by DNMT1 along with the E3 
ubiquitin-protein ligase (UHRF1).[85] Together, DNMT1 and UHRF1 associate with the 
replication machinery at the hemi-methylated parental DNA strand and faithfully transmit the 
DNA methylation pattern to the newly synthesized DNA.[86, 87] It was previously believed that 
DNMT1 alone can copy DNA methylation pattern and pass it across the successive cellular 
generations. However, it turned out that the maintenance of DNA methylation upon cellular 
division is cooperatively achieved by both the de novo DNMT3A/B and DNMT1.[78, 88, 89] 
The implication of DNA methylation in establishing chromatin conformation and regulating 
transcription cannot be explained by the conviction that the presence of 5-mC per se controls the 
access of either transcriptional machinery or chromatin modifiers. One would rather consider the 
crosstalk between such an epigenetic mark with the rest of epigenetic mechanisms including 
histone modifiers and chromatin remodelers. Here comes the importance of the reader proteins 
that recognize methylated CpG sites and accordingly mediate the function of DNA methylation. 
Two families of proteins read methylated CpGs, namely, the MBD family (MeCP2 and MBD1-4) 
and the BTB/POZ zinc finger containing family (ZBTB 4, 33 and 38 and Kaiso).[90, 91] These 
reader proteins implement the crosstalk between DNA methylation and histone modifications that 
are known to establish local or long-range heterochromatin structure. For instance, upon reading 
5-mC in the CpG contexts, MeCP2 recruits Suv39h1/2 which in turn catalyzes the methylation on 
lysine 9 on histone H3 tail, thus influences heterochromatinization and reinforces silencing.[92-
94]    
Despite the fact that DNA methylation is stable and not easily reversed, DNA methylation can be 
erased either passively during DNA replication or actively by dedicated demethylases including 
Ten Elven translocation family (TET1-3), activation induced deaminase (AID) and thymine DNA 
glycosylase (TDG).[95-97] The TETs belong to the Fe2+ and α-ketoglutarate (α-KG)-dependent 
dioxygenases, they catalyzes oxidative deamination of 5-mC, yielding intermediate products 
starting from 5-hydroxymethyl cytosine (5-hmC), which is further oxidized into 5-formyl cytosine 
(5-fC) and eventually into 5-carboxy cytosine (5-cC). Both 5-fC and 5-cC are subject to excision 
by TDG giving rise to (abasic) positions at the sites that were marked by methylation. Base 
excision repair (BER) is then elicited to restore cytosine residues in their original positions.[97, 
98]   
 
 
 
Figure 1. Integrative mode of action of TETs and TDG in the erasure of 5-mC by oxidative deamination. Shen L et 
al, Annu Rev Biochem, p588. The figure is modified and taken from[98] 
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Establishment of DNA methylation pattern is not merely a culminate consequence of the balance 
between the DNMTs and the TETs. It is rather governed by other factors. Perhaps, the bimodal 
distribution of DNA methylation at CpG sites across the different genomic context suggests an 
impact of intrinsic sequence-based features on setting the global pattern of DNA methylation.[64, 
86, 99] Moreover, with the attrition of indiscriminate methylation during the early stages of 
embryonic development, CpG dinucleotides in the context of CpG islands (CGIs) show 
diminished degrees of methylation, if any; which would support the aforementioned suggestion 
that DNA methylation, in the sense of its establishment and function, is first and foremost 
dependent on the genomic context. (Explained in the next section)   
 
Establishing bimodal pattern of DNA methylation: 
 
During the pre-implantation stage of the mammalian embryo’s life, the genome is subjected to a 
massive DNA methylation at CpG dinucleotides. Upon implantation, the differential DNA 
methylation pattern is established over the genome, by two counteracting waves: [63, 64, 74, 99] 
• An indiscriminate surge of de novo methylation of the majority, if not all CpG 
dinucleotides, that are sparsely distributed in a context called CpG oceans. 
• A mechanism comprised of a group of reinforcing loops that keep CpG dinucleotides 
within the context of CpG islands (CGIs) unmethylated. The protection of CGIs from 
methylation could be a consequence of either spontaneous or enzymatic 
demethylation. However, the shared features of CGIs better explain this predominant 
deficiency of methylated CpG dinucleotides within CGIs context.  
As pointed out above, it is very unlikely to accurately explain DNA methylation in terms of 
writers/erasers balance, without considering the genomic targets for methylation and how their 
intrinsic characteristics direct the bimodal DNA methylation profiles. Since DNA methylation 
takes place on CpG dinucleotides, it is of a prime importance to understand the distribution of 
these CpG dinucleotides over the mammalian genome, and to hyperlink this understanding to 
DNA methylation.   
The majority of the mammalian genomic elements are deprived of CpG dinucleotides; most 
probably because they are subject to intensive methylation during the early primordial stages of 
embryonic development. As a consequence of that, the majority of the methylated cytosines in 
CpG context undergo spontaneous deamination into thymine, thus explains the lack of CpG 
dinucleotides over the mammalian genomes.[64] The persistent CpG dinucleotides are scattered 
within long genomic elements (CpG oceans). On the other hand, CpG islands are relatively short 
(up to 1 KB), interspersed and both CpG and GC-rich genomic elements, that are punctuated by 
the CpG oceans. Such genomic elements harbor some intrinsic criteria that supposedly stand 
behind the predominant lack of methylation within their vicinities and place them apart from the 
rest of the bulky genomic elements. CGIs share general sequence-based features, in spite of their 
sequence heterogeneity; they are adapted for a transcriptionally permissive and nucleosome-
depleted chromatin structure.[100, 101] It is suggested that the open structure of CGI regions is 
by default and is transcription-independent, evidenced by the finding that CGIs showed reluctance 
to assemble into nucleosomes in vitro.[102, 103] Consistently, CGIs have been shown to be well 
suited for promoter activity, even if they are remotely located with respect to any of the currently 
annotated promoters.[76]  
In embryonic stem cells and during pluripotency, CGIs have been shown to recruit transcription 
factors and RNA polymerase II (RNAPII), consistent to the fact that the genome of pluripotent 
cells is more permissive.[104] RNA polymerase then recruits the writers of the active histone 
mark H3K4me3, for example SETD1A/B, which in turn catalyzes the deposition of such histone 
mark that features active transcription. The CGIs are almost nucleosome depleted, yet flanked by 
nucleosomes that are embellished by H3K4me3. Methylation at any level of valence on H3K4 
impedes the binding of DNMT3L to the target CGI, thus prohibiting the assembly of the de novo 
methylation machinery that is comprised of DNTM3A/B and the non-catalytic DNMT3L.[105-
107] This in part explains the diminished level of CpG methylation within the CGI contexts and 
the bimodal patterns of DNA methylation. (Figure.2) 
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Figure 2. The establishment of bimodal DNA methylation pattern during pluripotency in CpG islands (top 
panel) and in CpG ocean context (bottom panel).  
 
 
DNA methylation and transcriptional regulation: 
 
DNA methylation as an epigenetic mark was first introduced in 1948 by R.Hotchiss; however, the 
functions of DNA methylation was kind of obscure until the mid-1970s. The year 1975 witnessed 
two featured and independent publications by Arthur Riggs and Ryan Holliday; these key papers 
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suggested for the first time the direct implication of DNA methylation at CpG context in 
transcriptional silencing.[41, 77]  
What has been proposed by the 1970s epigenesists, has actually offered a principal conceptual 
frame for our understanding of epigenetic mechanisms. Nevertheless some of the concepts that 
were adopted that time became debatable. For instance, the relationship between DNA 
methylation and transcriptional regulation has raised remarkable controversies. 
Since the distribution of CpG dinucleotides and CGIs is bimodal, it is plausible enough to think of 
the influence of such genomic elements on DNA methylation and how the distribution of DNA 
methylation itself in the transcriptional unit affects gene expression. 
About 50% of the GCIs in human genome coincide with transcriptional start sites (TSS), while 
the rest is distributed between intergenic and intragenic regions.[64] The annotated promoters are 
classified generally into high-CGIs promoters (HCP) which accounts for 70% of human 
promoters and the rest is comprised of low to intermediate CGI contents. The former set of 
promoters is annotated to crucial genes that code for proteins that are involved in development 
and lineage specification, and require tightly controlled modes of regulation.[78]  
It is presumable that methylation at CGIs within TSS is associated to silencing of transcriptional 
initiation. However, the timing of DNA methylation with respect silencing is disputable and has 
not been clearly affirmed. Here is raised the intriguing question below:  
 
Does DNA methylation precede or pursue silencing of transcriptional initiation? 
 
Notably, based on the perceptions of how de novo methylation is established, it has been realized 
that nucleosomal DNA is a perfect substrate for the de novo methylation machinery comprised of 
DNMTs. Moreover, the de novo DNMTs are influenced by the epigenetic marks decorating the 
target nucleosomes; for instance DNMT3L binds to DNA wrapped on nucleosome lacking 
H3K4me3( Figure.2), emphasizing the adversarial relationship between DNA methylation and 
gene expression.  
This would raise the speculation that DNA methylation directly induces silencing of transcription. 
DNA methylation is rather supposed to be an additional regulatory layer that reinforces the long-
term silencing, evidenced by the finding that the promoters of the genes on the inactive X 
chromosomes become methylated after they are already silenced.[108] 
It was found that during differentiation, the pluripotency-related genes that are destined for 
silencing are silenced by certain repressors which in turn recruit a complex comprised of G9a, 
LSD1 and HDAC1 (Figure.3). Each component in this complex contribute to local 
heterochromatinization that is eventually mediated by heterochromatin protein (HP1), then de 
novo DNMTs are recruited to establish DNA methylation that serves as a “Lock” to reinforce 
heterochromatinization, and long-term silencing.[109] 
Nevertheless, the findings that knocking de novo DNMTS out is associated with impaired 
differentiation of hematopoietic stem cells suggest the indispensability of DNA methylation for 
silencing pluripotency-associated genes and proper development and that in turn favors the 
postulation that DNA methylation acts upstream to silencing of transcriptional initiation. 
Bottom line, the relationship between DNA methylation and silencing seems to be bi-directional, 
it can proceed in either direction; however, no universal conceptual conclusion has come to affirm 
the issue of the timing of methylation with respect to silencing so far. 
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Figure 3. DNA methylation in silencing of pluripotency-genes 
 
 
Does DNA methylation involve in active gene expression? 
 
Interestingly, DNA methylation in the intragenic CGIs (also called Orphan GCIs) has been shown 
to be associated with active gene expression. As mentioned above, the location of methylated 
CpG dinucleotides in the transcriptional unit is a determining factor that directs the functionality 
of DNA methylation. Consistent to the bimodal distribution of CGIs, methylation of CpG in their 
vicinities show a differential behavior regarding the regulation of gene expression. 
Several functional lines have explained how CpG methylation marks the gene body regions of 
actively transcribed genes.[110-113] Perhaps, the most prominent mechanism is that intragenic 
CpG methylation enhances transcriptional elongation through inhibiting the cryptic intragenic 
transcription that overlap with the corresponding transcription.[114, 115] In line with the notion 
that CGIs are adapted for promoter activity, integrative analyses of Global Run on (GRO-seq) and 
transcriptome datasets have characterized many intragenic CGIs that code for non-coding or anti-
sense transcripts. These transcripts have been shown to attenuate the transcriptional elongation of 
the corresponding protein coding transcript.[116, 117] It is most likely that methylation of these 
cryptic promoters, functions in the suppression of their transcriptional potentials, thereby boosting 
the elongation of the corresponding gene transcription. In line with this notion, it was found that 
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the recruitment of DNMT3 at gene bodies is dependent on SETD2-mediated H3K36me3 
deposition, the intragenic mark of active transcription.[118, 119]  
Thus, despite the universality of the de novo methylation enzymes, the mechanism of establishing 
DNA methylation, in the sense of the factors that recruit DNMTs, is differential between 
promoter/TSS and gene bodies. This suggests that DNA methylation is not functioning separately 
from the genomic contexts and other epigenetic mechanisms, and casts doubts on the hypothesis 
that DNA methylation is the direct cause of transcriptional silencing, or transactivation. 
 
DNA methylation in Cancer: 
 
Altered methylome is considered as one of the most notorious features of human malignant 
diseases. Aberrant DNA methylation pattern has been found to contribute to the neoplastic 
transformation, as it is followed by altered gene expression profile which in turn expedites the 
acquisition of cancer hallmarks, boost mutational rate, and implement the phenotypic 
transformation of incipient cell into neoplastic cell with the greatest clonal advantages and 
eventually form a macroscopic tumor.  
In most solid as well as hematopoietic malignancies, a global hypomethylation, in particular in the 
intergenic CGIs has been observed.[120-124] In addition to global loss of methylation, regional 
hypermethylation is also a feature of human neoplasms. The exceptionally high frequency of 
hypermethylation at certain CpG-rich promoters of tumor suppressor genes in cancer is not taking 
place spontaneously or stochastically as was thought previously. This has turned out to be a rather 
highly coordinated and epigenetically attributed event referred to as CpG islands methylator 
phenotype (CIMP).[28] CIMP is a phenomenon of an epigenetically addictive phenotype, where 
regional hypermethylation at certain CpG contexts has been found to be of a significant biological 
relevance to certain subsets of colorectal cancer and glioblastoma; meaning that the genes that are 
prone to hypermethylation are not the same in all cancer types or subsets.[27, 119, 125-127]  
Recently, Pan-cancer analysis including whole-genome bisulfite sequencing data from normal 
tissues and their respective solid tumors showed a strong correlation between gene body 
hypermethylation and increased expression of 43% of homeobox genes in several cancers, 
supporting the idea that aberrant DNA methylation in cancer is not random.[128] The integrative 
Pan-cancer analysis revealed that a subset of under-methylated regions (> 3.5 kb) in normal 
tissues and are mostly enriched in proto-oncogenes involved in transcriptional regulation and 
control of differentiation. These regions are called (Methylation Canyons) and are prone to 
hypermethylation in cancers; in particular at the intragenic locations of signature oncogenes, 
thereby increase their expression in cancer.[128-130]  
It was found that certain sets of genes in embryonic stem cells that are silenced by PRC2-
mediated H3K27 trimethylation during pluripotency are prone to methylation in a cancer-type 
dependent manner.[131-133] Upon normal differentiation and lineage specification, PRC2 is 
released from the promoters CGIs, so that these genes are actively transcribed. Interestingly, with 
the development of neoplasms, the regions that were pre-marked with PRC2 during pluripotency 
become methylated and silenced[133, 134]; indicating that DNA methylation mirrors the pattern 
of PRC2-mediated silencing in stem cells, and thus establishes a state of pseudo-pluripotency that 
favors the unrestrained proliferation and cellular plasticity.[132, 134-136]  
In conclusion, DNA methylation, in terms of its functions, establishment and crosstalk to other 
epigenetic mechanisms, is highly influenced by genomic context, as well as both normal cellular 
conditions and disease types, and thus reciprocates to cellular programming in either situation.  
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1.2.5 Histone modifications 
 
Another facet of epigenetic mechanisms is the post-translational modification of certain amino 
acid residues on histone tails, most prominent candidate is lysine modification. Several chemical 
modifications of histones take place and involve in establishing structurally and functionally 
distinct chromatin domains.[43] Notably, post-translational modification is accomplished by 
adding a group or moiety to the side chain of the amino acid residue. These moieties could be 
phosphate, sumoyl, ubiquitinyl, acetyl, or methyl groups.[137-140] Similar to DNA methylation, 
a histone modification is established by a “writer” and removed by an “eraser” and is also 
recognized by a reader via a special domain and function in recruiting downstream effectors, thus 
local chromatin features are established.[55, 141] Hereby, I focus mainly on histone lysine 
methylation marks, in particular, methylation of lysine 27 on histone 3 (H3K27me) the repressive 
prototype of PRC2. 
 
What makes histone lysine methylation distinct amid the rest of post-translational 
modification features, for instance lysine acetylation?  
 
It is actually an intriguing question that comes to the minds of those who are into the field of 
epigenetics and chromatin. Several approaches can offer explanation to the distinctiveness of 
histone lysine methylation; the chemistry of lysine side chain, the functionalities of histone 
methylation marks and their crosstalk with the other epigenetic modifications, and the influence 
of the level of methylation in terms of valence on the local chromatin conformation and 
transcriptional potentials.    
Based on the chemical structure, lysine is one of the basic amino acid, its side chain contains ε-
amino group (-NH3+), rendering the side chain positively charged. When the side chain amino 
group is acetylated, the net positive charge is then neutralized, thus attenuating the electrostatic 
interaction between the net positively charged core histones within the nucleosome with the 
negatively charged backbone of the DNA wrapping around. Stressing that histone lysine 
acetylation is a mark of actively transcribed promoters and active enhancer elements; histone 
lysine acetylation, for example H3K27Ac, is associated with open chromatin structure and 
transcriptionally permissive conformation.[142-144] 
On the other hand, methylation of histone lysine can take place at three levels of valence, mono-, 
di- and up to trimethylation, without altering the electrostatic interaction between DNA and core 
histones (Figure.4).[55, 145]  This suggests that the epigenetic functioning of histone methylation 
marks does not hinge on disrupting the packaging of DNA around histones, and in agreement with 
the fact that histone lysine methylation marks can be associated with either active or repressed 
chromatin structures, depending on the position of lysine residue on histone tails as well as the 
valence of methylation. For instance, methylation at lysine residues 4, 36 and 79 are marks of 
active euchromatic loci, while methylation on lysine residues 9 and 27 are prototypical marks of 
long-range silencing at constitutive heterochromatin and of facultative heterochromatin, 
respectively.[40, 55, 145-149] 
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Figure 4. Lysine acetylation and methylation, edited and taken from ATDBio Nucleic Acids Book 
(www.atdbio.com)  
 
Thus, lysine methylation exerts differential functions in different genomic context and not 
tethered to a single mode of action, on the contrary to histone lysine acetylation.  
The establishment of histone methylation at lysine residues is accomplished by writers that harbor 
histone methyl transferase activity (HMT); such catalytic activity is mainly mediated by Su(var)3-
9, Enhancer of Zeste, and Trithorax (SET) domain[150, 151]. While the reversal of histone lysine 
methylation marks is mainly catalyzed by Jumonji C (JmjC) domain-containing lysine 
demethylases (KDMs).[152-154] However, Some histone lysine methylation features such as 
methylation at lysine 79 on H3 tails has been shown to be catalyzed by DOT1L, while no 
dedicated eraser has been characterized so far.[155] With the lack of an eraser to such mark, the 
levels of methylation in terms of methylation valence have been shown to be in part dependent on 
the rate of nucleosomal turnover. Recently, it has been found that the processive kinetics of 
writing H3K79 methylation is adversely influenced by the high rate of nucleosome exchange.[69] 
By devising a chemical induced proximity model, a DOT1L fusion protein was targeted to certain 
loci with different transcriptional potential and different nucleosomal exchange rates, yet, 
deprived of H3K79me marks in mouse embryonic stem cells (mESC). Interestingly, the findings 
suggested that the dynamicity of the genomic locus favors the lower methylation status, 
independently of an eraser activity. Integration of datasets from ChIP seq, RNA seq and CATCH-
IT seq in mESCs, provided parameters to Monte Carlo simulations that were extended to other 
histone methylation marks including H3K4 and H3K27 methylation marks. These simulations 
depicted the influence of nucleosome turnover on the methylation valences and revealed that 
lower methylation states are associated with the highly dynamic regions with higher 
transcriptional potentials. Consistently, it was surprisingly found that monomethylation of H3K27 
(H3K27me1) is a mark of actively transcribed genes when deposited at their respective intragenic 
regions (gene bodies); whilst dimethylation (H3K27me2) marks were shown to be enriched at the 
intergenic regions, preventing the firing of non-cell type specific enhancers and are associated 
with a poised transcriptional activity.[156] Later, it was confirmed that the gene body-deposited 
(H3K27me1) marks are not intermediate products of PRC2 towards the ultimate 
trimethylation[157], in an agreement with the finding that H3K27me1 is dependent in large part 
on SETD2-mediated H3K36me3 deposition at active gene bodies.[156] 
Altogether these findings reveals that histone methylations in terms of their establishment, 
epigenetic functioning is highly governed by the lysine residue, the methylation valence and 
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genomic context, and thus emphasize the distinctive placement of histone lysine methylation 
among the epigenetic mechanisms ever known. 
 
Establishing histone methylation patterns: 
 
As pointed out above, histone lysine methylation marks are not exclusive signs of a solitary 
chromatin status, they rather show a diversity of epigenetic facets of chromatin domains 
organization. In this section, I briefly explain the different classes of histone methylation 
machinery, specifically the antagonizing complexes that belong to two broad categories of 
chromatin modifying factors, Polycomb and Trithorax families.  
Throughout the past seven decades, two key evolutionarily conserved chromatin modifiers, 
namely, Polycomb (PcG) and Trithorax (TrxG) group proteins has been viewed as integral parts 
of epigenetic cellular memory system, wherein they function in opposition to maintain repressed 
and active gene expression states, respectively. They were first discovered in Drosophila 
melanogaster, and were introduced as epigenetic gatekeepers that orchestrate the expression of 
Homeotic (HOX) genes, thereby, function in controlling body segmentation plans during 
embryonic development.[158-162]  
During the last decade, extensive research has highlighted the functional diversity of both PcG 
and TrxG group proteins, which has expanded beyond merely regulating HOX genes expression. 
Such diversity is lucid in their implication in controlling a plethora of cellular and developmental 
processes including cell cycle control, proliferation, X chromosome inactivation, genomic 
imprinting, and regulation of stemness and development of cancer upon their aberrations.[163] 
These multiple functionalities hinge mainly on their ability to regulate chromatin on a wide-scale, 
ranging from local chromatin structural conformation to the three-dimensional organization of the 
genome. The wide-range chromatin organization is highly context dependent, in the sense that the 
assembly of the components of PcG and TrxG complexes takes place in a cell type- and 
developmental stage-specific manner; thus granting their abilities to spatio-temporally regulate 
genome in response to the varying cellular conditions.[163-166] 
I. Trithorax (TrxG) complexes:    
Trithorax members are highly heterogeneous, and thus play a widespread role in transcriptional 
activation and oppose the repressive activities exerted by polycomb in multiple ways. Trithorax 
category is subdivided in three different subcategories: 
• Switch/ sucrose non-fermentable (SWI/SNF): a family that includes two groups, 
namely BAF and PBAF. Each is comprised of up to 15 accessory subunits that are 
uniquely assembled around core subunits (BRM/BRG1) that harbor ATPase activity, 
by which they mediate chromatin remodeling.[162, 165-168]  
• ASH1: this subcategory includes proteins, the HMT activity of which is directed to 
write H3K36 methylation marks [169-171]; in addition, CBP which catalyzes H3K27 
acetylation is also included.[172, 173]  
• COMPASS family:  the COMPASS subcategory of TrxG is associated with the 
histone lysine4 methylation which is attributed to active transcription. Perhaps the 
most prominent group in terms of its evolutionary conservation and the unique 
functionality in establishing the bulk H3K4 trimethylation is the SET1/COMPASS 
group.[174] The different complexes of COMPASS share a consensus group of core 
subunits, around which other accessory proteins assemble. The core complex is 
comprised of WDR5, ASH2, RBBP5 and DPY30; collectively the core complex is 
abbreviated as “WARD”.[163, 174, 175] 
With the evolution of metazoans and the emergence of more complicated cis-
elements, the SET1/COMPASS complex as experience divergence that gave rise to 
other combinations, namely the MLL1/2 COMPASS-like and MLL3/4 COMPASS-
like. The former is functioning in catalyzing H3K4 trimethylation at certain subset of 
HOX genes and at bivalent promoter[176, 177]; while the latter mediates 
monomethylation (H3K4me1) at active enhancers.[174] Thus, the emergence of 
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these new combinations of COMPASS complex matches the increasing evolutionary 
complexity of the metazoan genomes.   
 
II. Polycomb (PcG) complexes: 
 
Despite their adversarial relationship, the complexities and evolutionary conservation of PcG and 
TrxG are matching to each other. Biochemical purification-based studies have viewed polycomb 
group proteins as of two cooperating, even if not necessarily redundant entities: Polycomb 
repressive complex1 (PRC1) which catalyzes mono-ubiquitination of lysine119 on histone H2A 
(H2AK119ub) and Polycomb repressive complex2 (PRC2) that functions in depositing the 
repressive prototype of facultative heterochromatin (H3K27me3).[163] Evolutionarily, PRC2 
seems to have evolved later than PRC1, evidenced by the absence of PRC2 in the common model 
organisms, budding and fission yeast.[178, 179] The evolution of metazoans was accompanied by 
the emergence of a partnership between both PRC1 and 2, suggesting their Lamarckian evolution 
to match the complexity of metazoan genome organization in terms of establishment of 
facultative heterochromatin.  
In mammals, both PRC1 and PRC2 exist in different combinations, wherein mutually exclusive 
sub-stoichiometric components that assemble to their respective core complexes; thus, exhibiting 
different modes of interactions (Figure.5). More tellingly, PRC1 for example is subdivided into: 
Canonical (cPRC1) and non-canonical (ncPRC1).[180] Both cPRC1 and ncPRC1 share a highly 
interspecies-conserved core complex, which comprised of: 
• RING1A/B: the catalytic subunit that harbors E3 ubiquitin ligase activity that 
establishes H2AK119ub.  
• Polycomb group ring-finger domain proteins (PCGF1-PCGF6), one of these six 
proteins should exist and considered as determining factor of the other accessory 
subunits that assemble to it. For example for the specification of cPRC1, a 
chromobox (CBX2, 4, 6-8), in addition to one of the polyhomeotic homologous 
proteins (PHC1-3) assemble around PCGF2/4.[163, 181] Whilst, the presence of 
zinc-finger and YY1 binding protein (RYBP) or its paralog YAF2 specifies the non-
canonical PRC1 and define the enzymatic activity and the mode of interaction with 
PRC2 as well.[182, 183]. 
It was previously though that the relationship between PRC1 and PRC2 is unidirectional, in the 
sense that H3K27me3 the product of PRC2 is recognized by the chromodomain of CBX subunit 
of cPRC1, and then triggers the RING 1A/B to catalyze H2AK119 mono-ubiquitination which 
leads to stoppage of the RNA polymerase II to reinforce silencing. Nevertheless, the discovery of 
the diverse combinations of PRC1 revealed that the crosstalk between PRC1 and 2 is bi-
directional, so that PRC1 can function independently of PRC2 or may even function in its 
recruitment as well. It has become well understood that the relationship between them is rather 
cooperative not hierarchical. The next section focuses on PRC2 functions and modes of 
recruitment to its genomic targets; therein, the crosstalk between PRC2 and PRC1 is explained in 
more details. 
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Figure 5. A) PRC1 assembly and specifications  B) PRC1/PRC2 interaction 
 
1.2.6 Polycomb repressive complex 2 (PRC2) 
 
The specification of cellular lineage and preservation of cellular identities through the successive 
generations require tight control over transcriptional states. This in turn entails an intricate 
network of transcription factors that work in harmony with chromatin associated factors that 
represent additional regulatory layers contributing to transcriptional control.[184] Of these 
chromatin associated factors, are the PcG group proteins that are known to function in reinforcing 
transcriptional repression. Perhaps PRC2 is well studied and well known to be altered in many 
solid as well as hematopoietic malignancies; thus, has been rendered a promising therapeutic 
target for many cancer types.[185, 186] 
PRC2 has been both intensively and extensively studied, and known to exclusively establish all 
levels of methylation at lysine 27 on H3 (H3K27me1/me2/me3), each shows distinct distribution 
over the different genomic loci.[156, 157, 184] The establishment of either methylation valence 
on H3K27 is directly implemented by the SET domain of the core subunit Ehnancer of Zeste 
homolog 2 (EZH2) or its closely related homolog EZH1.[187] The SET domain harbors histone 
lysine methyl transferase activity (HMT), that is it has a binding pocket that accommodate the 
substrate H3K27, which is right adjacent the site where the cofactor S-adenosyl Methionine 
(SAM) resides. The SAM represents the methyl group donor; the methyl group is then transferred 
to the amino group of H3K27 side chain in an ordered manner so that the ultimate product is 
trimethylated H3K27 (H3K27me3).[188, 189]    
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The HMT activity exerted by the SET domain of EZH2 has been shown to be exclusively 
responsible for establishing the three valences of H2K27me which are characterized by distinct 
functional disruptions across the genomic domains (as discussed in 1.2.5). This actually points out 
to the diversity of the aspects of PRC2, in terms of the factors influencing the HMT activity, the 
residence time of PRC2 subunits, the mechanisms of PRC2 recruitment that constitutes the 
regional preferences of PRC2 and differential deposition of the various H3K27 methylation 
marks. One general and plausible explanation of such diversity is the existence of PRC2 in 
different subsets like PRC1.[183, 186] Biochemical and structural studies have revealed that the 
catalytic SET domain of EZH2 is rendered “auto-inhibited” if solitarily occurs, indicating the 
importance of the other regulatory subunits for the functionality of the PRC2 holoenzyme.[189, 
190] Analogous to PRC1, It has been shown that PRC2 occurs in two main subsets, namely 
PRC2.1 and PRC2.2 (Figure.6). These two subsets share three core subunits including the 
aforementioned catalytic EZH2, in addition to Suppressor of Zeste12 (SUZ12) and Embryonic 
ectoderm development (EED).[184, 191] Together, in an equimolar stoichiometry, the three 
subunits comprise the core PRC2 complex around which other accessory subunits assemble in 
sub-stoichiometric combinations, giving rise to either PRC2.1 or PRC2.2. It is suggested that 
these sub-stoichiometric interactions are transient and are more likely to be lineage- and 
developmental stage-specific.  
 
 
 
 
 
 
 
 
Figure 6. The assembly of PRC2 core subunits with accessory components into PRC2.1 and PRC2.2 
subsets 
 
 
 
 
 
 
 
 
¨ 
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The core subunit SUZ12 doesn’t possess any enzymatic activities; however, it represents a 
docking station for the structural assembly of the other core as well as the accessory subunits 
(Figure.6). The C-terminus of SUZ12 contains VEFS domain around which assemble the core 
subunits EZH2 and EED; while the accessory subunits assemble to either of the N-terminal 
domains. For instance, the specification of PRC2.1 is achieved upon chromo-like domain 
mediated the interaction of one of three Polycomb-like proteins (PCL1-3) to the C2 domain of 
SUZ12; in addition, in mutually exclusive manner, either EPOP or PALI interacts to the Zn.B.Zn 
domain of SUZ12. On the other hand, for the assembly of PRC2.2, AEBP2 and JARID2 bind to 
Zn.B.Zn domain of SUZ12 via C2BH3K4 and trans-repression (TR) domains respectively.[190, 
192, 193]  
The occurrence of these subsets of PRC2 matches to its diversity and may in part explain the 
mechanisms of influencing the catalytic activity of PRC2 holoenzyme and the cellular condition-
dependent recruitment of PRC2. In other words, this might explain the plasticity of PRC2 in 
controlling mammalian genomes. (See below) 
 
 
The “Write and read” activity of PRC2: 
 
Given that the absence of at least the core regulatory subunits EED and SUZ12 renders the SET 
domain of EZH2 auto-inhibited and apart from the modes of PRC2 recruitment to their genomic 
targets, the catalytic activity mediated by SET domain is allosterically regulated. Moreover, a key 
feature of PRC2 is the self-contained or self-perpetuation mechanisms, which explains the 
positive feedback loop that functions in the further enhancement of the HMT activity of SET 
domain upon recognizing its product (H3K27me3) by the WD40 domains within the aromatic 
cage of EED. It is true that this feature is not exclusive to PRC2; SUV39H1/2, the H3K9 methyl 
transferase exhibits a double activity of both writing and reading H3K9me.[191] On the other 
hand, the writing and reading activities are mediated by two core subunits, EZH2 and EED, 
respectively. Thus, the mode and pattern of interaction between these two subunits is crucial for 
understanding the “write and read” mechanism and how such interactions functions in the 
allosteric regulation of the SET domain of EZH2. Structural studies have unraveled the domains 
of EZH2 and the modes of interaction between EZH2 and EED (figure).  
The EZH2 protein is subdivided into three main lobes, the N-terminal lobe (N-lobe), the middle 
lobe, and the C-terminal catalytic lobe that harbors the SET domain. As illustrated in figure, the 
N-lobe is comprised of six domains, the first of them (SBD) packs against the last (SANT1), 
forming a closed lasso around the aromatic cage of EED.[189] The WD40 domains of EED´s 
aromatic cage bind and recognize H3K27me3, thus undergoing conformational restructure which 
in turn induce the reorganization of SRM domain of EZH2 from its basal disordered state. The 
SRM is comprised of helical structures which interact to the helices of the post-SET portion 
(SET-I) by hydrophobic interactions, leading to release of SET-I portion that basally keeps the 
structure of SET domain suboptimal.[189, 190]  
The self-perpetuating mode of action of PRC2 and the allotment of the writer and reading 
activities between EZH2 and EED respectively highlights the flexibility and dynamicity of PRC2 
that matches its implication in establishing local facultative heterochromatin regions.[191, 194, 
195] Furthermore, the existence of PRC2 in sub-stoichiometric subsets depending on the 
accessory subunits supports the idea that PRC2 is dynamically influenced in context dependent 
fashion. The modes of PRC2 recruitment over the genome during the different cellular conditions 
and how this in turn influence the catalytic activity would foster the understanding of the diversity 
and dynamicity of PRC2 in chromatin regulation.     
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Figure 7. A) Map of EZH2 domains and the pattern of interaction with and looping around the aromatic cage-
containing portion of EED. B) An illustration of self “write and read” mechanism of PRC2. 
 
 
Targeting and recruitment of PRC2 over chromatin: 
 
With the evolution of mammalian genomes, some elements have emerged, while other 
disappeared. Of note, in Drosophila melanogaster, polycomb complexes have been shown to be 
recruited at cis-elements termed Polycomb-response elements (PREs), thus providing a direct 
mechanism for locating PcG over the genome.[196, 197] On the contrary, the targeting of 
polycomb proteins in mammals is not that straightforward, evidenced by ChIP-seq studies that 
revealed that the regions enriched with H3K27 methylation, except few, are lacking PRC2 
subunits, which highlight the “hit and run” nature of PRC2 and its transient residence over the 
majority of the genomic regions. PRC2 has no sequence-specific DNA binding motifs and its 
recruitment to its target loci relies on a plethora of factors that are after all governed by the cell 
type and the stage of differentiation.[184, 191, 198] 
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As mentioned in the previous sections, PRC2 exist in different combinations that share the core 
subunits EZH2, EED and SUZ12 and depending on the accessory proteins that assemble to the 
core complex, the subsets are differentially targeted to the genomic regions. In addition to the 
structural importance of SUZ12 for assembling PRC2 subsets, it plays an integral role in locating 
PRC2 preferentially at unmethylated, transcriptionally repressed CGIs. In this regard, SUZ12 
relies on its N-terminal portion for recruiting proteins that possess DNA binding properties. For 
instance AEBP2 which binds at either C2 or Zn.B.Zn domains of SUZ12, harbors at its C-
terminus a zinc finger domain that binds to DNA and thus was suggested as a recruiter of PRC2; 
however it was proven not be that efficient.[184, 191] 
During pluripotency, PRC2 was found to preferentially occur in the PRC2.2 subset that contains 
both AEBP2 and JARID2.[199, 200] This latter contains JmjN and ARID domains that serve in 
loading PRC2 on nucleosomes and CGIs respectively; also JARID2 functions in allosteric 
regulation of SET domain activity in a way that mimics the write and read mechanism, thus 
establishing H3K27me3 profiles during the early stages of differentiation. On the other side, 
terminally differentiated cells prefers the PRC2.1 subset, wherein either of PCL proteins assemble 
to SUZ12, and by virtue of EH domain, it mediates the recruitment of PRC2 to CGI-rich regions. 
Accordingly, unmethylated CGIs are suggested to be the mammalian alternatives for PREs in flies 
and underscore the importance to investigate the mechanistic link between DNA methylation and 
PRC2.[201, 202]    
Long non-coding RNAs have been also proven as efficient means for targeting PRC2 at the 
parentally imprinted alleles and inactive X-chromosome in females.[59, 203] Surprisingly, the 
actively transcribed genes during pluripotency have been involved in capturing PRC2[58], in the 
sense that nascent mRNAs compete with chromatin to bind at PRC2, in particular the middle lobe 
of EZH2. Notably the binding of the nascent transcripts of active genes and the presence of other 
active marks including H3K4me3 and H3K36me3 inhibit the catalytic activity of PRC2, yet 
tethering it within the vicinities of the actively expressed gene that might be destined for silencing 
upon lineage specification, when PRC2 is then liberated to catalyze heterochromatinization 
silencing.[184, 191] Thus, PRC2 is suggested to serve a transcriptional sensory function. The 
recruitment of PRC2 and how it influences its catalytic activity is becoming increasingly 
understood, yet, needs to be more deeply portrayed. 
 
PRC2 accurately establishes H3K27 methylation patterns de novo: 
 
Given that PRC2 has no consensus binding sites over the mammalian genome, the self-
perpetuating, or the “write and read” mechanism is suggested to function in faithful restoration of 
H3K27 methylation patterns across the successive cellular division cycles. However, this 
postulation has become a matter of controversy. It has been found that as the genome is copied, 
H3K27 methylation shows two-fold dilution. In line with this, the knock-out of PRC2 core 
components in mESCs was found associated with global loss of H3K27 methylation pattern, 
while ectopic re-expression of PRC2 components resulted in restoration of H3K27me patterns at 
the same original loci in wild-type counterparts.[157] This suggests that PRC2 can establish 
H3K27me profiles de novo, and that the self-maintenance mechanisms partially serve to this 
endeavor, in particular during DNA replication.  
This postulation is supported by several aspects: 
• First, the deposition of lower levels of H3K27me within the genomic regions of 
differential transcriptional properties is less likely to be consequences of demethylase 
(UTX) gain of function, and neither are these lower valences intermediates towards 
the ultimate trimethylation of H3K27. This notion indicate the deliberately diverse 
functionality of PRC2 in catalyzing the ad hoc H3K27 methylation patterns and 
support that these patterns are not established nor maintained haphazardly.[156, 157]     
• Second, the core subunit SUZ12 has been proven to play a substantial role in 
regulating PRC2-mediated H3K27 methylation.[184] Along with the assembly of the 
PRC2 core complex, it has been shown to locate at the PRC2 genomic targets 
independently of the other core subunits. Depending on either the EH domain of PCL 
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proteins or the ARID domain of JARID2, PRC2 binds to CGIs, hence implying an 
oriented functioning of PRC2.  
• Third, as explained above, the differential occurrence of PRC2 in sub-stoichiometries 
is specified by the stage of differentiation. More tellingly, JARID2 plays a dual role 
for directing and influencing PRC2 functions, in the sense that it not only helps direct 
placement of PRC2.2 to target regions during pluripotency, but also serves to 
allosterically activate SET domain of EZH2 to enhance its HMT activity to de novo 
establish H3K27 methylation at the transcriptionally permissive loci that are deprived 
of H3K27me3 and destined for silencing upon differentiation. Notably, JARID2 and 
EZH2 decline upon reaching terminal differentiation and the HMT activity is then 
dispensed by EZH1[200], emphasizing that the H3K27 patterns are established de 
novo by PRC2 during lineage commitment and point out to the active implication of 
PRC2 in maintaining H3K27me3 even in terminally differentiated cells. 
Altogether, these findings underscore the inadequacy of the self-maintenance mechanism to set 
the H3K27me profiles and confirm that they are deliberately established by PRC2 not passively 
by the self-perpetuating mechanism.   
 
Non-canonical implication of EZH2 in transcriptional activation: 
 
Along with the intensively understood facet of PRC2 in constituting additional regulatory layer 
that reinforce transcriptional silencing and establishing heterochromatin, other non-canonical 
aspects of PRC2 has been highlighted.[204-206] Interestingly, the catalytic subunit EZH2 has 
been viewed to serve oncogenic functions independently of its HMT activity and involves in 
methylating non-histone substrates; for instance it was found that upon its phosophorylation by 
Akt, EZH2 methylates and activates STAT3 in glioblastoma.[207] Also, EZH2 functions in 
inhibiting the interaction between the transcription factor GATA4 and p300 by methylating 
GATA4.[208] 
Surprisingly, anomalous behaviors of EZH in transcriptional activation have been reported.[209-
212] most prominently, EZH2 was found to exhibit a context-dependent double faced behavior in 
transcriptional regulation; more tellingly, EZH2 behave differently in two prognostic subgroups 
of breast cancer, namely the basal and luminal subsets.[213]  
Interestingly, in the aggressive basal breast carcinoma, EZH2 interacts with RelA and RelB and 
functions in activating the expression of NF-κB-related genes. On the other hand, these genes 
were found to be repressed by PRC2-dependent activity of EZH2 in the luminal subgroup with 
more favorable clinical prognosis. This further underscores the dynamicity and plasticity of PRC2 
in response to the cellular context. Given that the sole occurrence of EZH2 is associated with a 
loss of HMT activity and the interaction between the nascent transcripts of the actively expressed 
genes, the implication of PRC2 in transcriptional activation is not that strange and accordingly 
stresses on the importance of dissecting these non-canonical facets of PRC2 for comprehensive 
understanding of PRC2 in normal and diseased conditions.   
 
PRC2 a promising therapeutic target for cancer treatment: 
 
Several lines of evidence have reported the deregulation of PRC2-mediated H3K27 methylation 
patterns in solid as well as hematopoietic cancers.[163, 186, 189, 204] The aspects of PRC2 
aberration are differential among the various cancer types; either gain- or loss-of-functions 
encounter the different subunits of PRC2 in human malignancies. Accordingly, it has become of a 
prime importance to develop lines of treatment to circumvent the cancer-associated PRC2 
alterations.[214-216] 
Structural and cryo-EM-based studies have portrayed the mode of HMT activity of EZH2; this 
approach initiated developing chemical compound that selectively target the HMT activity of 
EZH2. Some of the potent inhibitors have been designed to competitively inhibit the binding of 
the cofactor SAM at its binding pockets, such as EPZ005687 and other similar compounds.[216] 
although several of these SAM-competitive inhibitors are currently in clinical trials, their 
therapeutic indices are restricted by the imperfect pharmacological properties in terms of the bio-
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availabilities and short half-time. Moreover, many tumors have been shown to exhibit resistance 
to these inhibitors; most citable is the gain-of function mutations (Y641X) in diffuse large B cell 
lymphoma (DLBCL). These substitution mutations along with other mutations in the vicinities of 
SET and SRM domains have been found to impede the binding of the SAM-competitive 
inhibitors, thus eliciting resistance to such therapies. Thus, the need to elaborate other lines of 
therapies that target PRC2 is tremendous. 
Recently, other lines of treatment have been developed to target the self-maintenance of PRC2, in 
particular the aromatic cage of EED and block its binding to H3K27me3 and abrogate the 
initiation of H3K27me3-potentiated positive feedback loop.[190] Also, the other oncogenic 
activities exerted by EZH2 in a PRC2-independent manner have also to be considered. In this 
regard, other chemical compounds, like gambogenic acid derivatives have been developed to 
target the stability of EZH2 at protein level and induce its ubiquitin-mediated proteolysis; 
however, this line has to be adequately studied.[217] 
Throughout the past decade, many ground-breaking studies have enhanced our understanding of 
PRC2 in terms of its recruitment, catalysis and diverse functionalities. The progressive 
understanding of PRC2 and its crosstalk with PRC1 and other epigenetic mechanism has proved 
such chromatin associated factor as highly dynamic and context specific that needs 
comprehensive and detailed understanding, which along with the personalized medicine might 
pave platforms for developing more efficient lines of treatment and improve the life quality of 
cancer patients.          
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1.3 Chronic lymphocytic leukemia (CLL) 
1.3.1 CLL overview 
 
Chronic Lymphocytic Leukemia (CLL) is a lymphoproliferative malignancy of CD5+ B 
lymphocytes that is characterized by increased number of CD5+, CD19+, CD23+ small and 
mature-looking leukemic B cells in peripheral blood and secondary lymphoid tissues, resulting in 
lymphocytosis, splenomegaly, bone marrow infiltration and lymphadenopathy.[218, 219]  It is the 
most frequent hematopoietic malignancy in the west[220] and is common among the elders in 
particular and the median age of CLL diagnosis is ~70 years.[221-223] 
The risk of CLL incidence is two-folds in males compared to females.[224, 225]  CLL shows a 
heterogeneous clinical progression among patients; so that it ranges from patients with indolent 
disease and do not necessarily require therapy for so many years post-diagnosis, if any at all, to a 
more deadly aggressive disease that requires immediate treatment soon after diagnosis. 
 Such clinical heterogeneity renders CLL a hard-to-cure disease. Multiple factors like patients’ 
age, genomic alterations and mutations, presence of comorbidities, in addition to the mutational 
status of immunoglobulin´s heavy chain variable region gene segment (IGHV) should be taken 
into the physicians´ considerations to decide the treatment lines and define the optimal therapeutic 
strategies.[218, 219, 226, 227] The latter factor is among the most important to consider, in this 
case the inhibitors of B cell receptor signaling or receptor tyrosine kinase inhibitors are suitable 
treatment options.[228-231]   
New insights have progressively been gained and shed lights on both genomic and epigenomic 
patterns in CLL, which turned out to be at least in part associated to the clinical heterogeneity and 
disease aggressiveness.[232, 233] Here, CLL is our cancer model where we investigate the 
aberrant epigenetic profile in terms of DNA methylation and chromatin architectural anomalies as 
a consequence of polycomb repressive complex deregulation and show how this influences the 
gene expression profile of CLL which is in turn implicated in the disease aggression. 
1.3.2 CLL pathobiology 
  
Normal B cell development: 
 
To understand the pathobiology of CLL, the development and maturation of B lymphocytes has to 
be understood. In bone marrow, the process of B cell development starts at hematopoietic stem 
cells (HSC), wherein interactions with stromal cells and nurse-like cells that comprise the 
specialized bone marrow microenvironment influence the maturation and activation of B cells in 
three ways: 
• First, they specifically form adhesive contact with the developing lymphocytes 
via cell-adhesion molecules and their respective ligand on the stromal cells 
• Second, the stromal cells provide either soluble or membrane-bound cytokines 
and chemokines that control differentiation and proliferation 
• Third, these interactions leads to activation of downstream signaling that 
eventually leads to activation of lineage-specific transcription factors and then 
changes in the gene expression core regulatory circuits that serve in the 
commitment of specific cell lineage.     
More tellingly, the  stromal cells secretes interleukin-7 (IL-7) that binds to its cognate receptor on 
the surface of the common lymphoid progenitor (CLP), the IL-7 signaling then induces the 
expression of PU.1 and E2A transcription factors, which in turn function in activation of early B 
cell factor (EBF).[234] EBF specifies B-lineage via activating other B-lineage specific 
transcription factor PAX-5 and inducing the expression of the components of V[D]J 
recombination machinery (RAG-1 and RAG-2).[235] PAX-5 is known as a B-cell activator which 
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induces the expression of cell surface signatures of B lymphocytes CD19, BLNK and Igα; thus 
promulgating the development of Progenitor B cells (Pro-B cells).[236] 
After the B-lineage is specified in the bone marrow, the process of immunoglobulin gene 
rearrangement start in early progenitor B cells (early Pro-B cells), wherein, the D[J] segment 
rearrangement of the heavy chain portion starts and upon its completion, early Pro-B gives rise to 
late Pro-B  cell. In late Pro-B cell, the already rearranged D[J] segment recombines with one 
variable (v) segment and upon the completion of  VH[D]JH recombination process, late Pro-B cell 
develop into a large precursor B cell (Pre-B cell). The Pre-B cells carry a µ-heavy chain and with 
the development into small Pre-B cell, the process of light chain of immunoglobulin gene VLJL 
rearrangement starts. After the VLJL rearrangement is successfully done, the small Pre-B cell 
gives rise to an immature B cell that carries on its surface a pre-B cell receptor (pre-BCR), which 
is comprised of a µ-heavy chain and a surrogate light chain (Vpre B, λ5).[237]  
The immature B lymphocytes are then subject for antigen experiencing; as centroblasts, immature 
B cells migrate to lymph nodes where the process of maturation and antigen stimulation takes 
place. The maturation of B cells is bifurcate, in the sense that it can either take place inside the 
germinal centers of the lymphoid follicles or at the marginal zone region. In the germinal centers, 
the centroblast immature B cell, experience antigen stimulation in T helper cell-dependent manner 
and the rearranged immunoglobulin heavy chain variable gene (IGHV) is subject to somatic 
hypermutations; thus coding for variable binding pockets to a variety of antigens. Whereas, the 
marginal zone maturation takes place in a T cell independent way and the somatic hypermutations 
are not obligatory, if any, the difference in homology compared to germline would be less than 
2%, and the antigen stimulation takes place in response to bacterial lipopolysaccharides.[238, 
239]  
During antigen stimulation, those centroblasts that show no binding affinities towards antigens or 
bind to self-antigens are subject for negative selection and elimination by apoptosis; while those 
the properly bind to antigens would mature into centrocytes, that can mature to either antigen-
experience memory B cells or plasma cells. Bottom line, the mature B cells are not monoclonal 
and can either harbor somatic hypermutations to their IGHV genes or do not.  The process of B 
cell development and maturation from Pro-B cells till mature antigen-experienced B lymphocytes 
is illustrated in Figure.8.  
 
Where does B-CLL originate from? 
 
In the past, chronic lymphocytic leukemia was viewed as a disease of homogeneous origin and 
heterogeneous clinical course.[240] It was thought that CLL originates from long lived, immature 
and immuno-incompetent (Naïve) B lymphocytes. Until the end of the nineties of the last century, 
CLL was considered as a disease of accumulation, in the sense that leukemic B cells of 
diminished self-renewal potential relentlessly accumulate as a consequence of an inherent 
apoptotic aberrations.[239, 240] 
This view has been dramatically transformed thanks to the wealth of progressive insights have 
been gained. CLL is by now viewed as a both clinically and clonally heterogeneous disease of 
two related entities originating from antigen-experienced B lymphocytes that differ in their 
activation, interaction to the microenvironment and immunoglobulin heavy chain variable region 
gene (IGHV) mutational status.[239, 241] Such heterogeneity ranges from relatively indolent 
disease course to a more aggressive, incurable and poor prognostic disease.[242] In addition, there 
is no inherent faulty apoptotic mechanisms encounter the entire mass of leukemic B cells. [243, 
244] In this sense, CLL is not merely considered as a disease of accumulation anymore. 
Based on the mutational status of IGHV genes, CLL is sub-grouped into two entities of distinct 
clinical outcomes, the more favorable IGHV-mutated CLL that originate from follicular mature B 
cell that has matured inside the germinal centers, and the clinically adverse IGHV-unmutated 
CLL that develop form marginal zone mature B lymphocytes, where very few or no mutations has 
been introduced to the rearranged IGHV genes. The latter is attributed with poor prognosis and 
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inferior clinical outcomes that can be rationalized by BCR restriction and sustainable proliferative 
signaling (explained below).[239, 242]  
 
 
  
 
Figure 8. B lymphocytes development and maturation 
 
 
 
 
 
Genome-wide epigenetic profiling of B cell leukemia and lymphoma 
28 
CLL pathogenesis: 
 
In most cases, CLL is preceded by an indolent disease called monoclonal B cell lymphocytosis 
(MBL)[245], which arises from either follicular mature B cells or marginal zone mature B cells, 
giving rise to either IGHV-mutated or unmutated CLL, respectively.    
Over the time of CLL development, a small fraction can give rise to an atrociously aggressive 
stage of the disease called Richter’s syndrome that is associated with poor survival.[246] 
The progression of CLL hinges on some promoting factors including the reactivity of BCR, the 
interaction of the microenvironment and the altered signaling pathways. I hereby focus on BCR 
signaling and its link to the microenvironment and the affected pathways that contribute to the 
disease progression and how it impacts on the clinical outcomes of the disease.  Also, I explain 
some of the recurrent mutations and cytogenetic aberration in CLL and whether they are cut out 
for being inducing factors of CLL development or promoting agents that emerge during the 
disease progression. Thus, I pave the way of the discussion of the significance of epigenetic 
patterns in CLL development.  
 
B Cell Receptors (BCRs) signaling: 
 
The immunoglobulin molecules repertoire made by CLL cells is more limited than that made by 
normal B lymphocytes. Given the number of possible V-gene segment recombinations that code 
for antigen-binding site on the immunoglobulin molecules, it would never be anticipated to find 
two among one million of CLL cases express structurally similar BCRs.[247] However, it has 
surprisingly found that various CLL patients show high degree of structural similarity, indicating 
that BCRs in CLL preferentially bind to certain antigens that are relevant to CLL pathogenesis. 
This further suggests that in CLL, there is a bias toward a special pattern of VHDJH 
recombination, rendering antigen-binding pocket more restricted to certain antigens to which 
BCR are hyper-reactive compared to the much broader diversity in normal B cell counterparts. 
These certain promoting antigens are unknown; however it is believed that CLL may result 
directly or indirectly from specific latent viral perpetuated infections in a way that resembles the 
case of gastric carcinoma development as a consequence of Helicobacter pylori infection.[248] 
The structural similarity of BCRs is considered as a brand by which the various CLL cases can be 
grouped into distinct categories. Such BCR restriction along with poly-reactivity highlights the 
substantial role of BCR signaling in CLL pathogenesis and promotion. The restricted BCR 
repertoire in CLL may also explain why CLL patients with unmutated IGHV genes exhibit much 
more adverse clinical outcomes compared to those with IGHV mutations.[247, 249]    
Engagement of BCR with microenvironment:  
As aforementioned that CLL has been shown to arise from mature, antigen-stimulated B 
lymphocytes that show abnormal B cell receptors (BCR) reactivity, in the sense that these 
receptors may show hyper-reactivity towards the microenvironment and autoantigens which can 
provoke clonal expansion. Upon interaction with microenvironment, BCRs interact to some 
accessory cells e.g. stromal cells and nurse-like cells and others that respond to cytokines and 
chemokines produced by those accessory cells. Thus, stimuli are delivered through receptor 
tyrosine kinases like Lyn, Syk and BTK which leads to stimulation of proliferative pathways 
including NOTCH, PI3K/AKT, mTOR, NF-κB and wnt/ β-Catenin pathways leading to 
uncontrolled proliferation and neoplastic transformation.[250, 251] 
Cytogenetic lesions and mutations in CLL: 
 
In line with the heterogeneity of CLL clinical course, cytogenetic alterations that have been 
associated with the prognosis of CLL patients are also heterogeneous.[252] Early cytogenetic 
analysis revealed a marked heterogeneity, at both inter-patient and intra-patient levels. 
A landmark study was conducted on a large CLL cohort to comprehensively identify the 
mutational landscape in CLL using fluorescence in situ hybridization (FISH).[221] the findings of 
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this study underscored the most prominent cytogenetic lesions and copy number alteration in CLL 
and showed their differential occurrence among the different CLL patients. 
Perhaps the most frequent cytogenetic lesion is del (13q14) which takes place in approximately 
50% of CLL patients and is associated with kind of a good clinical outcome. The genes that are 
affected upon this deletion are mainly tumor suppressors and they include MIR15A/MIR16-1 and 
DLEU2. Despite the fact that this cytogenetic aberration is associated with good prognosis, some 
sets of patients carrying this alteration at the locus of the tumor suppressor RB1, are showing 
more aggressive disease course.[253] The second most common cytogenetic alteration is trisomy 
12, and it is associated with some driver mutations that affect NOTCH1 and BIRC3 genes, which 
are in turn associated with altered NOTCH signaling and NF-κB pathway, respectively.[254] 
Mutations that afflict NOTCH1 gene occurs at a frequency of 10% of CLL patients and this 
frequency increases to up to 40% in the most adverse stage of CLL, the Richter syndrome.[255] 
Coming after these two hallmark lesions, are del (11q22-23), del (17p13) and del (6q21) and 
others that take place at much lower frequencies in CLL patients. These lesions are associated 
with notorious mutations that are correlated with poor prognosis and much more aggressive 
clinical course of CLL.[256] The cytogenetic lesion del (11q22-23) occurs at up to 20% 
frequency and is associated with altered DNA repair system, as a consequence of ATM loss[257]; 
whereas del (17p13) is associated with the loss of the gate-keeper TP53 leading to a serious 
adverse clinical outcome. Less frequently, del (6q21) occurs in CLL patients and is mainly 
associated with aberration in transcriptional regulation as a result of ZNF292 loss.[221, 239, 252]  
Several ominous point mutations to crucial genes for CLL biology have been identified. Perhaps 
most prominently are mutations of SF3B1 which is of 20% frequency and is associated to altered 
RNA splicing and processing and eventually altered gene expression in CLL. Mutations and 
cytogenetic lesions are heterogeneous among CLL patients and are bona fide contributors to CLL 
prognosis.   
  
1.3.3 CLL epigenome 
 
Genetic lesions: inducing or promoting factors? 
 
Considering the earlier adopted approach that cancer is a disease of mutations and the monoclonal 
nature of leukemic B cells (B-CLL), one might think that an inducing lesion must have existed in 
the progenitor clone and accordingly such lesion is supposed to be an inducing factor of the 
disease. However, even before the rise of the massively parallel technologies, the cytogenetic 
lesions were found to be very rare during the early course of CLL; thus arguing that mutations 
and cytogenetic lesions are the actual inducer of transformation of normal B lymphocytes to B-
CLL. Moreover, among the other hematological malignancies and compared to other solid 
tumors, CLL is distinct by its relatively stable genome and the scarcity of chromosomal 
translocations.   
One more aspect of CLL distinctiveness is that the mutational load is much less compared to other 
cancers; the average of mutational burden in CLL is approximately 1 mutation / megabase. 
Therefore, it is very unlikely that mutations and cytogenetic aberrations are inducing factors of 
CLL development; they rather emerge with the progression of the disease to a range of clinically 
heterogeneous courses. As pointed out above, the heterogeneity is not only observed between the 
different patients. This heterogeneity of cytogenetic lesion is also intra-patient, in the sense that 
some mutations and lesions are sub-clonal, meaning that they are acquired or present in only a 
fraction of the B-CLL pool in the same patient.  
Bottom line, there is no unifying cytogenetic lesion or mutation identified so far as a universal 
attribute of CLL; thus supporting the counter argument to the idea that mutations/lesions are the 
factors that stand behind the development of CLL from normal B lymphocytes. This is also 
implies that there should be highly context specific mechanisms that encompass the emergence of 
mutations and the impaired proliferative pathways that are most likely to be of the hallmark 
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characteristics that are acquired as CLL progresses and underscore the importance of epigenetic 
mechanisms as candidate “enabling” factors of CLL development.     
 
CLL aggressiveness is embedded in an aberrant epigenome: 
 
As discussed previously that that mutational load of cancer might not qualify “mutations” as 
inducing factors of neoplastic transformation. Also, aberrant gene expression profile is surrogate 
of the cellular reprogramming and implements the manifestation of neoplastic or malignant 
phenotype. In CLL, the complex molecular pathogenesis substantially hinges on aberrant BCR 
signaling, making it a promising therapeutic target. The significance of BCR signaling in CLL 
progression is evidenced by the success of BCR inhibitors like ibrutinib in improving patients’ 
prognosis. However, there are no unifying or recurring mutations found to encounter BCR 
signaling-related genes in CLL. Thus, it is of utmost importance to dissect the epigenome of CLL 
and its link to inter- and intra-patients heterogeneity.  
Altered DNA methylation is of the most prominent hallmarks of CLL and has been extensively 
studied. A global loss of DNA methylation in CLL and regional preference to hypermethylation 
and the relevance of such altered methylome to CLL progression are well documented by several 
studies.[258-262] the findings of these studies suggested DNA methylation as a prognostic factor 
that can serve in stratification of CLL subtypes and shed the lights on the relevance of altered 
DNA methylation in reprogramming of transcription factors dependencies and altering gene 
expression regulatory circuits that establish a malignancy-specific epigenome. 
Also, it was found that hypomethylation at LINE and Alu elements is associated with genomic 
instabilities in CLL, which supports the idea that altered epigenetic mechanisms encompass the 
cytogenetic lesions, the impact of which in CLL progression is secondary to aberrant 
epigenome.[263] 
Moreover, it has been shown that all cell types display asymmetrical patterns of enhancer 
potentials, pointing out to a set of super-enhancers that have been found to be cancer-type-
specific.[264] In CLL, integration of global histone acetylation and chromatin accessibility data 
revealed CLL-specific super-enhancers mediating the CLL-transcription factor core 
circuitry.[265] This study identified PAX-5 as a core regulator of CLL super-enhancers essential 
for B-CLL survival and pointed that targeting of CLL-super-enhancer circuits is a promising line 
of therapy. 
A recent study has been conducted on a cohort of 23 CLL patients and 17 pools of CD19+ sorted 
out from healthy age-matched participants to comprehensively portray the altered epigenome in 
CLL.[266] Histone modification of 7 marks (H3K4me1, H3K4me3, H3K27me3, H3K9me3, 
H3K36me3, H3K27Ac and H3K9Ac) were assessed by ChIP-seq; the peak regions of each of 
these marks, along with transcriptome analysis by RNA-seq, were used as input to the 12 state 
ChromHMM Hidden Markov model for genome segmentation and accordingly addressing the 
epigenetic transitions of chromatin states between normal B cells and CLL. Also, this study 
mapped the differentially accessible regions by ATAC-seq and MNase-seq, in addition to global 
methylome assessment by whole genome bisulfite sequencing (WGBS). Integration of ChIP-seq, 
RNA-seq and MNase-seq data revealed a set of genes regulated by alternative promoters in CLL; 
in the sense that some promoters were found to extend their H3K4me3-regions by 2 nucleosomes 
(≈400bp). Consistently, these extended promoter loci lost ATAC-signals and found to be mainly 
enriched to BCR signaling-related genes. Moreover, 1700 promoters that are bivalent in normal B 
cells were found to lose bivalency, in the sense that they lose H3K4me3 and retain H3K27me3 
and were found to be binding motifs for MEF2 family of transcription factors.   
ATAC-seq revealed that about 30% of the differentially accessible loci gained ATAC-signals in 
CLL compared to normal counterparts, while 70% of these loci were accessible in normal B cells 
and lost ATAC-signals in CLL. The loci that gained ATAC-seq were supposed to be bona fide 
transcription factor binding sites specific to CLL, and thus subjected to motif analysis of these 
loci by HOMER software. Gene regulatory network analysis using expression data of 264 B cell 
samples and RNA-seq of this study were intersected to motif analysis and revealed 1378 
regulators displayed differential activity between CLL and normal B cells (FDR > 0.05), the top 
four of which were FOXA1, LEF1, POU3F1 and REPIN1.  
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This integrative analysis could also predict potential CLL-specific enhancers; that is super-
enhancers were annotated by clusters of open chromatin regions (ATAC-signal gain), H3K27Ac 
(ChIP-seq) and bidirectional RNA expression (RNA-seq). Out of 1289 union super-enhancer, 310 
showed differential super-enhancer activities; 219 of these 310 showed upregulation of enhancer 
activity and defined CLL-specific super-enhancers. It was found that TCF4, CREB3L2, FMOD, 
LEF1, ETV6 and NFATC1 were supposedly upregulated genes by CLL-specific super-enhancer.  
Integration of all the data included in that study along with other ENCODE data underscored the 
deregulated CLL-signature genes and intersection of these genes with transcription factors of 
differential activities highlighted the aberrant regulators and target genes in CLL. 
 In line with others, the data of WGBS of that study revealed a global hypomethylation in CLL 
compared to normal B cells that was rationalized by partially methylated domains (PMDs) in 50% 
of the CLL genome. Interestingly, the repressive domains were overrepresented in PDMs and 
75% of the recurrent somatic mutations in CLL were found located in these PMD regions, 
consistent to the increased mutational burden at repressed domains and further confirming the 
idea that aberrant epigenome is upstream to mutations and cytogenetic lesions.  
Furthermore, 91% of the differentially methylated regions which are mainly hypomethylated were 
overlapped with predicted enhancers, suggesting the impact of differentia DNA methylation 
pattern in the asymmetric enhancer activity between normal B cells and B-CLL. 
What has been discovered so far indicate that inter- and intra- patient heterogeneity is 
epigenetically attributed; thus superimposing the complication of CLL as an incurable disease. 
This necessitates collaboration between epigenesists and physicians to stratify CLL patients’ 
prognosis based on their altered epigenome and dig for a unifying epigenetic aberration that might 
be a promising therapeutic target for generating more efficient treatment options for better 
prognoses.    
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2 AIM 
 
This work mainly focuses on probing the aberrant epigenetic patterns in CLL, in terms of global 
alteration of DNA methylation within the transcriptional units and the abnormal patterns of 
H3K27 methylation, and how these altered epigenetic patterns are involved in shaping the gene 
expression profile in CLL. The thesis includes three studies the unifying goal of which is to 
scrutinize the mechanisms by which the aberrant epigenome is implicated in the deregulation of 
signature genes that are of biological relevance to CLL progression. 
2.1 Specific aims 
 
I. Investigate the mechanism elicited by gene body methylation in transcriptional 
activation of TET1 as a candidate model gene to address the implication of 
methylation within the intragenic regions of the gene that are prone to 
hypermethyltion in CLL compared to normal B cell counterparts. (Paper 1) 
II. Global mapping of H3K27 methylation patterns and genome-wide distribution of its 
writer EZH2 in two prognostic subgroups of CLL patients. In addition to uncover a 
possible PRC2-independent implication of EZH2 in activation of PI3K/AKT 
pathway through transcriptional activation of IGF1R in IGHV-unmutated CLL the 
worse prognostic subtype. (Paper 2) 
III. Draw a functional link between intragenic CpG islands methylation and the 
functionality of PRC2, in terms of its localization and catalytic activity and probe the 
possible mechanism behind the adversarial relationship between PRC2 and CpG 
islands hypermethylation in controlling the expression of MNX1 in CLL. 
(manuscript) 
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3 PATIENTS AND METHODS 
3.1 Patients cohort 
Total 40 CLL patient samples (twenty U-CLL and twenty M-CLL) were used in Paper 1 and 
Paper 3. The peripheral blood mononuclear cells (PBMCs) CLL samples were collected from 
different hematology departments in the western part of Sweden after written consent had been 
obtained and is approved by Regionala etikprovningsniimnden in Gothenburg (decision number: 
197-18). All samples were diagnosed according to contemporary iWCLL criteria for the time of 
sampling, showing typical CLL immunophenotype and 70% or more tumor percentage. The 
median age at diagnosis was 66 years, with a male: female ratio of 3: 2. For comparison to normal 
counterparts, five DNA samples of CD+19 sorted normal B cells from healthy age matched 
controls were purchased from 3H biomedical (Uppsala, Sweden). 
Sorting of B lymphocytes was performed using autoMacs protocol from the respective buffy 
coats. 
Paper 2 was conducted using a cohort of 113 CLL patients with evaluated molecular and clinical 
data. Out of these samples, 12 cases (six U-CLL and six M-CLL) were subjected to ChIP-seq to 
map EZH2 and H3K27me3 patterns, 16 samples were included in validation experiments to ChIP-
seq data; these 16 samples along with the rest (n=82) were used for assessing expression levels of 
EZH2 and IGF1R using real-time PCR analysis, and the data were used for Pearson correlation 
analysis. The sample provision has been approved by the G. Papanicolaou Hospital ethics 
committee (decision number: 149/27.3.2015). CLL patients were diagnosed according to the 
iwCLL criteria.[267] The patients were either untreated by the sampling time or off-therapy for at 
least 6 months before the time of sampling.  
All patients provided informed consents in accordance with the Helsinki Declaration and the 
study was approved by the local ethics review boards. 
3.2 Methods  
1. DNA methylation assessment by Pyrosequencing: 
The principle on which pyrosequencing is based, is the sequence-by-synthesis approach[268]; 
more tellingly, a single stranded DNA molecule serves as a template for progressively 
incorporated labelled deoxyribonucleotide triphosphate (dNTPs) by DNA polymerase. This 
method is also substantially based on bisulfite conversion of DNA, the subject of methylation 
assessment. Unmethylated cytosine bases in either CGI or non-CGI contexts are subject for 
deamination into uracil upon bisulfite conversion reaction, while methylation at fifth position of 
cytosine (5-mC) remains intact. Thus, methylated cytosine can be detected by other downstream 
applications including whole genome bisulfite sequencing (WGBS) or reduced representation 
bisulfite sequencing (RRBS) and other methods. In this work, pyrosequencing was the mean of 
assessing DNA methylation patterns in CLL patients. The bisulfite converted DNA of probe is 
subjected to PCR amplification using two primers designed by Pyromark software, so that one of 
them is biotinylated. The PCR amplicon is then immobilized to high-performance streptavidin 
sepharose beads by CLICK-IT chemistry and is then denatured into single stranded template that 
anneals to a designed sequencing primer; from this step, starts the sequencing-by-synthesis 
process. The sequencing-by-synthesis process takes place inside Pyromark machine, wherein the 
sequencing immobilized biotinylated single stranded on sepharose beads which is also annealed to 
the respective sequencing primer is in contact with dNTPs, enzyme mixture which is comprised 
of DNA polymerase, ATP sulfurylase, luciferase and apyrase, and the substrate mixture that 
contains luciferin and adenosine 5’ phosphosulfate (APS). After incorporation of each dNTP onto 
the single stranded DNA template by the polymerase, a pyrophosphate is released and reacts to 
APS yielding an ATP by ATP sulfurylase. The ATP is in turn drives the action of luciferase in 
converting luciferin into oxyluciferin that generates visible light proportional to the consumed 
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ATP that corresponds to each incorporated dNTPs. The light signal is then detected and recorded 
as a peak in the pyrogram. The peaks are surrogates of nucleotides sequence and the CGI sites as 
well as methylation % are inferred on the pyrogram. 
 
2. Measuring promoter activity by luciferase reporter assay: 
The transcriptional potential of either enhancer or promoter genomic elements can be assessed by 
inserting the genomic sequence of interest into luciferase reporter vector (e.g. PGL3 vectors) in 
comparison of coexisting β-galactosidase reporter gene.[269] The high sensitivity of the assay 
allows the discrimination of transcriptional activities of elements that show minor difference in 
their respective potentials. The transcriptional potential of the inserted sequence accordingly 
influence the expression of the reporter gene (luciferase). The sequence of investigation is cloned 
into reporter vector and transfected into transfection-tolerant cell lines; perhaps MCF-7 and HEK 
are of the best candidates. After a considerable time of growing the cells post-transfection, 
preferably at a time that exceeds the doubling time of the cells, the transfected cells are then lysed 
and incubated with luciferin and other cofactors like ATP. As described in the previous section, 
the expressed luciferase catalyzed the oxidation of luciferin into oxyluciferin in an ATPase-
coupled reaction. The light emitted is detected and quantified by luminometer as light units which 
are in turn normalized over the β-galactosidase activity; thus the relative light units are measures 
of the relative luciferase activity which represents the transcriptional potential in turn.      
  
3. Chromatin immunoprecipitation (ChIP) 
The ChIP method aims at assessing DNA-protein interaction and identification of transcription 
factor binding sites at certain genomic regions, in addition it can assess chromatin status by 
determination of certain histone post-translational modification marks.[270, 271] The principle of 
this method hinges on fixing the cells of study by 1% formaldehyde for 10-15 minutes, so that 
chromatin is crosslinked to its associated proteins or histones. The fixation process is supposed to 
be not longer than 15 minutes and to quench the formaldehyde mediated crosslinking, 125 uM 
Glycine should be added to the fixed cells. Next, the fixed cells are subject to lysis and the 
crosslinked chromatin should be exposed to shearing by either enzymatic means using restriction 
enzymes, or by random sonication (30 second ON/ 30 seconds OFF) so that the sheared smear is 
supposed to range from 100- 500 bp long. The sheared chromatin is then subject for 
immunoprecipitation using high quality ChIP-grade antibody for the transcription factor, 
chromatin modifier or histone mark of probe. The antibody can be crosslinked to protein A/G- 
coated magnetic beads. The immunoprecipitation reaction takes up to 16 hours at 4oC, then the 
beads crosslinked with the antibody-DNA is then subject for washing by buffers containing 
gradient concentrations of detergent. The washed beads-antibody-DNA is then subjected for de-
crosslinking in the presence of proteinase K, so that all DNA-binding proteins, histones and beads 
are released and the DNA sequences are then eluted and used for downstream applications, either 
high throughput sequencing platforms (explained below) or amplified by ChIP-real time PCR 
(explained in section 3.3). 
 
4. Hight throughput sequencing and bioinformatics analysis: 
 
4.A. ChIP-sequencing (ChIP-seq): 
ChIP was performed on 12  CLL samples using the Ideal ChIP seq kit (Diagenode, C01010051) 
according to the manufacturer’s protocol using an EZH2 polyclonal antibody (Diagenode, 
C15410039) and an H3K27me3 polyclonal antibody (Diagenode, C15410069). 
The general workflow of ChIP includes: 
• Preparation of cDNA libraries, with considerable number of reads (40-50 million 
reads/ sample) and the read length at 2 * 100 bp. 
• A quality check is performed using FastQ software, and then the reads are 
filtered based on their quality using TrimeGalore software. 
• The filtered reads are then subject for alignment to human reference genome 
assembly GRCh37/hg19 using Bowtie2. 
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• Quality check by cross correlation, cumulative enrichment and clustering were 
performed using phantompeakqualtools and deepTools. 
• Removal of the duplicates and blacklisted-mapped-reads is carried out by Picard 
• Peak calling is performed with MACS2, with a minimum FDR (q-value) cut-off 
for peak detection of 0.05. 
• Normalization of peaks with their corresponding input using deepTools2. 
• Annotation of peaks in different genomic regions using W-score with cutoff 0.1 
and 0.01and finding unique peaks by BedTools. 
• The average profile and density heatmaps obtained for window sizes +/- 5KB of 
transcriptional start sites (TSS) in M-CLL and U-CLL were plotted using 
deepTools2. 
• The pathways enriched in EZH2 and H3K27me3 overlapping regions of each 
CLL subgroups were identified using ChIP-Enrich. 
The general workflow is described in detail in paper 2[272] and illustrated in figure.8.  
 
 
 
 
Figure 9. ChIP-seq workflow 
 
 
 
4.B. RNA-sequencing (RNA-seq): 
RNA samples extracted form CLL cell lines were subject to cDNA library preparation. The 
libraries construction and sequencing were performed by Novogene (Hong Kong) using Illumina 
HiSeq 2500 platform. The single-end cleaned reads were aligned to human genome assembly 
GRCh37/hg19 using STAR aligner version 2.5.2b [273], and the alignment quality was further 
assessed using SAMStat tool[274]. The high quality of reads mapping score was considered 
(MAPQ≥30) for downstream quantification based on gencode version 19 annotation using with 
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the aid of featureCounts [275], excluding the multi-mapped reads. To calculate the differential 
expression statistics, edgeR Bioconductor package was used[276]. The statistical false discovery 
rate (FDR) was set at a cut-off <0.05 for multiple comparisons and expression log2 fold change ≥ 
±1. Pathways enrichment analysis of differentially expressed genes was done using GeneSCF tool 
(5) and considered a statistical cut-off value of 0.05 for the enriched pathways.[277]  
3.3 Laboratory assays 
 
Cell culture and maintenance: 
Two CLL cell lines, namely HG3[278] and MEC1[279] along with other mantle cell lymphoma 
cell lines (Z138, GRANTA 519, Jeko and Mino) were used to conduct the experiments of the 
three studies included in this thesis. Cell lines were cultured in RPMI 1640 containing L-
glutamine and supplemented with 10% fetal bovine serum and 1X penicillin/streptomycin and 
maintained at 37oC and 5% CO2 as earlier described [280]. To investigate the effect of CpG 
methylation on gene expression in paper 1 and the manuscript, cells were treated with the 5’-Aza-
2’-deoxycytidine (DAC) methyl inhibitor using CLL cell lines cultured in RPMI media at an 
optimal concentration 30uM according to a previously described protocol.[123]   also, 3-
Deazaneplanocin (DZNep) and JQ treatment of cell lines were performed to inhibit EZH2 and c-
MYC respectively for three days using different concentrations. Similarly, the usage of chemical 
inhibitors that target the catalytic activity (GSK 343 and UNC1999), in addition to Idelalisib the 
inhibitor of PI3K/AKT pathway were performed using cell lines as described in details in paper 
2.[272]  
 
Transfection: 
Transient transfection by electroporation was carried out by Amaxa 4D-Nucleofector™ System 
(Lonza group AG, Basel, Switzerland) using the SF cell line Amaxa kit (V4XC-2032) according 
to the manufacturer’s instruction. 50nM of Predesigned Stealth RNAi siRNAs were utilized 
against EZH2, c-MYC, IGF1R (ThermoFischer Scientific, Waltham, USA) in equal 
concentrations. The silencer negative control siRNA (ThermoFischer Scientific, Waltham, USA) 
was used as control siRNA. The transfected cells were kept and maintained for one doubling time 
(48-72 h) depending on the type on the used cell lines. This protocol was also applied for 
overexpressing miR26A1 and PGL3 vector containing-TET1 HMR as described in paper 1.[281] 
 
RNA extraction and cDNA synthesis: 
RNA was extracted from CLL PBMC samples using RNA Extraction Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. DNAse1 treatment was performed to remove 
any residual genomic DNA during RNA extractions.  The total cDNA synthesis was performed 
using Superscript III FS synthesis supermix kit (Life technologies, Carlsbad, USA) according to 
the manufacturer’s protocol.  For cell lines, RNA extraction was performed using Relia Prep RNA 
miniprep system kit, Promega according to the protocol provided by the manufacturer. cDNA 
samples was prepared from their respective RNA using GoScript Reverse transcription system kit 
(A5000, Promega) in compliance to the producer´s protocol. 
The extracted RNA samples that were destined for RNA sequencing were subjected for 
concentration and quality analysis by Bioanalyzer 2100 before cDNA library preparation. 
 
Gene expression analysis by RT-PCR: 
Real-time PCR was performed using Power SYBR Green PCR master mix and the 7900HT fast 
real-time PCR instrument (Applied Biosystems,Warrington, UK). Relative expression was 
calculated and normalized to HPRT and/or GAPDH genes. The relative expression levels were 
calculated by the ΔΔCt method. 
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DNA extraction, Bisulfite conversion: 
DNA extraction from CLL PBMC samples and CLL cell lines was performed using DNA 
Extraction Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Bisulfite 
conversion of DNA was performed to assess DNA methylation by using EZ DNA Methylation-
Gold kit (Cat # D5005). The eluted bisulfite converted DNA was subject for methylation analysis 
by pyrosequencing 
 
Pyrosequencing: 
Pyrosequencing was conducted on bisulfite converted DNA using PyroMark Q24, to assess 
differential methylation across some selected regions across MNX1 gene obtained from our 
previous global MBD-seq analysis and the primer sets were designed using (software) and listed 
in Supplementary table. The analysis of data obtained from PyroMark machine was analyzed by 
PyroMark Q24 Advance software. 
 
Protein expression estimation by western blotting: 
Western blot analysis was performed using total cell lysates lysed from transfected or drug-treated 
CLL cell line samples in RIPA buffer (Sigma-aldrich, St.Louis, USA) with PI inhibitors (Roche, 
Basel, Switzerland). Equal amounts of lysates were loaded on NuPAGE 4-12% Bis-Tris gels 
(Invitrogen, Carlsbad, USA) and transferred to membranes (Amersham Hybond ECL; GE Health 
Care Life Sciences, Sweden). Blocking of the membranes is performed in 5% BSA with TBS 
with addition of 0.1% Triton X-100, then the membranes were incubated with the appropriate 
primary and secondary antibodies, followed by washes with TBS containing 0.05% Triton X-100. 
The primary antibodies used for western blotting were: TET1 ( ab191698, Abcam, Cambridge, 
UK), EZH2 (3147, Cell Signaling Technology, Danvers, USA) and GAPDH (SC-25778; Santa 
Cruz Biotechnology, Dallas, USA), MYC (ab17355, Abcam), H3K27me3 (C15410069), 
H3K4me3 (C15410003), H3K27Ac (C15410174) polyclonal antibodies (Diagenode, Liege, 
Belgium), H3 (ab1791, Abcam), IGF1R (ab39675, Abcam), Phospho-Akt (Ser473; 9271) and 
AKT (9272) antibodies (Cell signaling technology, Netherlands). The secondary antibodies were 
anti-mouse IgG (7076S, Cell Signaling Technology, Danvers, USA) and anti-rabbit IgG (7074S, 
Cell Signaling Technology, Danvers, USA). Blots were developed using SuperSignal West Dura 
Extended Duration Substrate (Thermo Scientific, Rockford, USA) and the visualization is 
performed using the ChemiDoc XRSC (Bio-Rad) instrument. 
 
ChIP assay: 
ChIP assays were performed using the iDeal ChIP-seq kit (Diagenode, Liege, Belgium), 
according to the manufacturer’s instructions. The immunoprecipitation was conducted using 
antibodies against EZH2 (39876, Active motif), H3K27me3 (C15410069, Diagenode), 
H3K27me1 (C15410045-10, Diagenode), H3K36me3 (C1541092-10, Diagenode) and polyclonal 
rabbit anti-IgG (c15410206, Diagenode) as negative control.  
The final eluted DNA was analyzed by real-time quantitative PCR with the Power SYBR Green 
PCR master mix (Applied Biosystems, Warrington, UK). The PCR conditions were: 50 °C for 2 
min, 95 °C for 10 min, and 40 cycles of 95 °C for 15 s and 60 °C for 1 min. The PCR analysis 
was performed with the 7900HT fast real-time PCR system instrument and software (Applied 
Biosystems, Warrington, UK). All primers were designed by using PRIMER3 online tools. 
The calculation of enrichment was done according to the following formulas: 
• The % of IP to input formula:  
% recovery = 2^[(Ct input-log2(5%)) – Ct sample] * 100% 
• The enrichment was calculated as:  %recovery IP  / % recovery IgG   
The eluted ChIP DNA was quantified using Qubit 2 Florometer (ThermoFischer 
Scientific, Q32866) and around 10ng of ChIP DNA was used for preparing sequencing 
libraries by ThruPLEX-FD Prep Kit (Rubicon Genomics, Ann Arbor, USA) according to 
the manufacturer’s protocol. 
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Cloning: 
Two regions within the HMR region of TET1 that was identified by MBD-sequencing data 
analysis from a published study [120] (519 and 632 bp long) were amplified by PCR. The PCR 
primers were designed to contain Kpn1 and XhoI restriction sites at 5’- and 3’- ends respectively 
for positive orientation insertion of the sequence of interest and the other way around for negative 
orientation insertion. Restriction digestion of both PGL3 vector and the amplified sequences was 
performed by Kpn1 and XhoI; following that, mounting of both oriented sequences was performed 
by T4 ligase. The ligated inserts-vectors constructs were then transformed into TOPO10 
competent bacterial cells by heat shock followed by outgrowth in SOC medium and plating on LB 
agar containing ampicillin. Miniprep experiments were performed to select the optimal colonies 
for further outgrowth in LB medium containing ampicillin. Midiprep was then performed to 
eventually extract and purify the constructs in TE buffer. 
  
Dual Luciferase reporter assay: 
The dual-luciferase reporter assay system (Promega, Madison, USA) was performed in MCF-7 
cells transfected with PGL3 constructs by Lipofectamine LTX plus reagent kit (Invitrogen, 
Carlsbad, USA) according to the protocol supplied by the manufacturers. The relative light units 
were measured with a luminometer (Glomax 20/20 luminometer, Promega, Madison, USA). Each 
experiment included at least three independent biological replicates, and the final luciferase 
values (relative light units) were calculated by dividing the luciferase activity by the β-
galactosidase activity. 
 
Strand specific PCR:  
Specifically designed 5’GSP (Gene specific Primer) and 3’GSP were used for synthesizing gene 
specific cDNA from DNase1 treated RNA samples. The 5’GSP specifically binds to antisense 
strand and the 3’GSP binds to the sense strand. After cDNA synthesis, to quantify the strand 
specific cDNA synthesis we used two sets of primers which are located downstream to the 5’GSP 
and 3’GSP. The PCR conditions for amplification were 95°C for 10mins, 95°C for 30seconds, 
55°C for 30seconds, 72°C for 30seconds and 30 cycles of 95°C, 55°C and 72°C for 30seconds 
and finally 72°C for 3minutes. The amplified product was run in 1% agarose gel and visualized 
using the ChemiDoc XRS+ (Bio-Rad) instrument. 
3.4 Statistical analysis 
Statistical analysis was performed with STATISTICA 12.0 (Stat Soft, Tulsa, USA) and GraphPad 
Prism version 6 (GraphPad Software, La Jolla California, USA). Comparisons between groups 
were performed so that the cut-off of the level of statistical significance was set as (P < 0.05) 
For comparing any parameter (relative expression or methylation %) in CLL samples, unpaired t-
test was performed with Welch´s correction. The experiments that were conducted using cell lines 
included at least three independent biological replicates and the data were represented as (Mean ± 
SD). For comparisons, two-tailed t-test was performed, and the replicates were considered of 
equal variance for calculating p-values. 
For correlation analysis, Pearson correlation was performed on CLL patient samples to correlate 
two variables: (expression of EZH2 vs IGF1R; n=96). For the manuscript, Pearson correlation test 
was performed between -log10 relative expression values of MNX1 and –log10 of intragenic 
methylation percentage of MNX1 and the correlation was further supported by performing linear 
regression test, wherein methylation was set as independent variable (X) and expression as 
dependent (Y). Two-tailed t-test was performed to calculate p-value of Pearson correlation. 
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4 RESULTS AND DISCUSSION 
4.1 Paper 1 
 
Gene-body hypermethylation controlled cryptic promoter and miR26A1-dependent EZH2 
regulation of TET1 gene activity in chronic lymphocytic leukemia: 
 
A previous study of our group, by means of MBD-sequencing technique, has mapped the 
differential DNA methylation patterns in two subsets of chronic lymphocytic leukemia (CLL) 
patients (IGHV-mutated and unmutated CLL) in comparison to normal B cell counterparts that 
are sorted from peripheral blood samples of healthy donors.[120] This methylome analysis 
revealed sets of biologically relevant genes that are differentially hypermethylated in CLL versus 
healthy B cells. Out of these genes is Ten Eleven translocation 1 (TET1), the prominent eraser of 
5-methyl cytosine that elicits active demethylation of DNA and under certain circumstances might 
potentiate passive demethylation as well. According to this data, the gene body region of TET1 
was found to harbor higher degree of methylation in CLL; whilst the promoter does not show any 
differential pattern between CLL and normal B cells. The hypermethylated intragenic region of 
TET1 in CLL that is identified by MBD-seq is referred to as HMR. Interestingly, analyzing a 
published RNA-sequencing dataset on a large cohort of CLL patients (n=96) and 9 healthy 
controls revealed that TET1 is overexpressed in CLL compared to normal counterparts (logFC ≈ 
2; FDR < 0.001). 
The differential methylation and expression patterns of TET1 is validated in sorted B-CLL cells 
from an independent CLL sample cohort (n=40) versus sorted normal B cells from healthy donors 
(n=5) by Pyrosequencing and RT-PCR, respectively. Altogether, these findings suggest that the 
expression of TET1 is likely to be positively regulated by intragenic DNA methylation, in 
agreement to what has been found by other studies regarding the relationship between gene body 
methylation and transcriptional activation. 
To gain further insights on the mechanism underlying the transcriptional activation by gene body 
methylation, four leukemic cell lines were used as model system, wherein global demethylation 
was induced by 5-aza-2’-deoxycytidine (DAC) which competitively inhibit S-adenosyl 
methionine (SAM) binding at DNMTs. Upon DAC treatment in the cell lines, a significant 
reduction of the relative expression of TET1 mRNA, as well as reduced protein level were 
observed; thus increasing the likelihood that gene body hypermethylation functions in 
transcriptional activation of TET1. Moreover, transcriptome analysis in CLL cell lines treated 
with DAC and negative control counterparts, showed a significant reduction of TET1 upon DAC 
treatment (unpublished data). Intrigued by such finding, it was postulated that the HMR region of 
TET1 might harbor a cryptic promoter activity, which might be associated with antisense 
transcription that overlap with or attenuate the corresponding TET1 gene transcription. Cloning of 
this part of TET1 (519 bp) into a promoter-less PGL3 expression vector in both sense and 
antisense orientation revealed an exceedingly higher luciferase activity of the antisense 
orientation compared to a basic control vector, sense oriented HMR and SV40 as a positive 
control. This notion was then supported by the detection of intronic transcripts in B-CLL and 
normal B cells by RT-PCR using 7 sets of primers designed across HMR region.  
Of note, DAC treatment of cell lines was found associated with a significant increase of this 
intronic transcription along with reduction of TET1 mRNA, suggesting that methylation at this 
region contributes to activation of TET1 gene expression by suppressing this supposed intronic 
transcription. The postulation was then that intronic transcription might overlap with the 
corresponding gene expression; however fine mapping of the intronic transcripts by RT-PCR and 
strand-specific PCR revealed that the intronic transcription is not detectable at the regions 
downstream to HMR, indicating that the intronic transcription is not overlapping with the 
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corresponding promoter of TET1 and argue against the assumption that cryptic transcription 
converge and attenuate the corresponding transcription. In line with what has been viewed by 
other studies, this might be explained that the intronic transcription may be adversarial to 
transcriptional elongation; thereby it interferes with the corresponding transcript with no effect on 
the TET1 promoter activity itself. Global DNA hypomethylation with regional hypermethylation 
has been reported in CLL.[120, 122, 123, 282] This might consistently match to our observation 
that is TET1 overexpression in CLL, and might also explain one possible regulatory loop of active 
demethylation across the genome in CLL.  
 
Conclusion: 
 
Integration between our previous methylome dataset and a published transcriptome dataset of 
independent CLL cohorts, this study drew a functional link between intragenic DNA methylation 
and transcriptional activation of TET1 gene in terms of controlling a cryptic intronic transcription. 
Loss of methylation within the gene body regions is associated with firing of cryptic promoter and 
in turn intronic transcription that interfere with the corresponding gene activity. Thus, explaining 
the implication of preferential gene body hypermethylation in increased TET1 gene expression in 
CLL compared to normal B cellular counterparts.   
 
 
 
Figure 10. Graphical illustration explains the conclusion of paper 1.[281] 
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4.2 Paper 2 
EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically 
aggressive chronic lymphocytic leukaemia: 
 
Employing ChIP-seq technology, this study identified for the first time EZH2 target genes in two 
prognostic subsets of CLL, namely IGHV-mutated and unmutated CLL (M-CLL & U-CLL) 
patients. In addition, the genome-wide patterns of H3K27me3, the prototypical repressive mark of 
PRC2 has been identified in both subsets as well. By mapping and aligning EZH2-peak regions to 
the reference human genome (hg19), it was found that the majority of EZH2-target loci (63-67%) 
are annotated to promoter/TSS regions in both M-CLL and U-CLL patients, indicating a 
functional significance of EZH2 in transcriptional regulation in CLL. The similar pattern of EZH2 
distribution might somehow indicate a unifying role of EZH2 in both prognostic subgroups; 
supported by the notion that 90% of the total EZH2-target genes are found overlapped between 
MCLL and UCLL. Intriguingly, upon overlapping total EZH2-target genes with H3K27me3 
peaks with minimum 1 bp overlap, 2676 genes were obtained and are called EZH2-overlapped 
(EZH2-OP). The remaining 10239 genes (EZH2-NOP) were not overlapped with H3K27me3 
according to the strategy we have set for overlapping with at least 1 bp overlap. This could be 
explained by the transient nature of PRC2 and its “hit-and-run” mode of action, along with the 
lack of consensus binding sites over human genome. [184, 191] Moreover, the finding that 80% 
of EZH2 peaks in CLL (EZH2-NOP) are not enriched with H3K27me3, suggests that EZH2 
might function at certain loci independently of its being an integral part of PRC2. 
The focus of the study was then narrowed to the genes that are enriched with both EZH2 and its 
associated mark H3K27me3 (EZH2-OP), so that the likelihood that these genes are bona fide 
targets of PRC2 is enclosed. The overlap of EZH2-taget genes between mutated and unmutated 
CLL has reduced from 90% that was observed in the total EZH2-targets in CLL to 45% in the 
filtered EZH2-OP list of genes; thus offered a counterargument to the tentative assumption that 
EZH2 exhibit unifying functionality in both subsets of CLL. It turned out that EZH2 shows 
differential pattern of distribution in both subsets, evidenced by the result that 44.5% of EZH2-OP 
are specifically enriched with EZH2 in U-CLL. These findings so far suggest a functional 
relevance of EZH2 enrichment at the ad hoc set of genes in either subgroup. 
Analyzing a published RNA-seq datasets [283] revealed that approximately 30% of these EZH2-
OP genes are differentially expressed between MCLL and UCLL, hence further supports the 
subdivision of EZH2 mode of action in the two prognostic subgroups. Interestingly, the majority 
of these differentially expressed genes is upregulated in U-CLL; thus, indicating an implication of 
EZH2 in transcriptional activation in U-CLL. Next, KEGG pathway analysis of EZH2-OP genes 
revealed several oncogenic pathways; among the top significant of which is PI3K/Akt pathway. 
Interestingly, PI3K/Akt pathway-clustered genes were shown to be differentially enriched with 
EZH2 between both subgroups. Furthermore, integrative analysis of our ChIP-seq data and the 
published RNA-seq data revealed some of the 86 PI3K-genes including IGF1R are found to be 
significantly enriched with EZH2 and overexpressed in the poor prognostic UCLL compared to 
MCLL. According to our ChIP seq, EZH2 occurs at IGF1R promoter in unmutated CLL but not 
in mutated and RNA-seq analysis showed a significant overexpression of IGF1R in UCLL 
compared to MCLL (LogFC 1.41; p value 0.0001).  Intrigued by such notion, IGF1R was 
nominated as a model gene to probe a possible mechanism underlying a non-canonical 
implication of EZH2 in activating PI3K/AKT pathway-related genes in the CLL subgroup with 
worse prognosis. Using a large cohort of CLL (n=96), a positive correlation between relative 
expression of EZH2 and IGF1R was observed ( r = 0.58; p value < 0.0001); thus, the expression 
of IGF1R is more likely to be positively regulated by EZH2 in a PRC2-independent manner. This 
was evidenced by the significant reduced expression of IGF1R upon siRNA-mediated silencing of 
EZH2 in CLL cell line (HG3). Moreover, the reduced enrichment of EZH2 at IGF1R was not 
associated by any significant change of H3K27me3, highlighting an HMT-independent mode of 
action of EZH2; this was evidenced by the insignificant effect of using SAM-inhibitors (GSK343 
and UNC1999) on the level of phosphorylated AKT (p-AKT) in HG3 cell line. 
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Our findings also revealed that EZH2 recruits c-MYC at IGF1R promoter, which in turn 
supposedly functions through its trans-activating domain in active expression of IGF1R, 
evidenced by the significant c-MYC-siRNA-associated IGF1R reduction in a way comparable to 
the effect of EZH2. The recruitment of c-MYC by EZH2 was further confirmed by ChIP-PCR 
which showed nonsignificant effect of c-MYC silencing on EZH2 enrichment; and neither does 
EZH2 silencing result in affecting c-MYC at mRNA level, as revealed by expression analysis by 
RT-PCR.   
 
Conclusion: 
 
Our ChIP-seq data identified for the first time the target genes of EZH2 and the global pattern of 
H3K27me3 in two subsets of CLL and such pattern led to characterize a hitherto unknown mode 
of action of EZH2 in active gene expression independently on PRC2 in a clinically adverse 
subgroup of CLL. This role of EZH2 seems to be of biological relevance to cancer type or 
subtype, illustrated here by activating PI3K-related signature genes including IGF1R specifically 
unmutated CLL (UCLL), thereby it partially contribute to the disease aggressiveness. 
Understanding the non-canonical facets of EZH2 might pave the way for more effective 
therapeutic lines that target PRC2 and circumvent the resistance exhibited by many cancers to 
SAM-inhibitors that target the HMT activity of PRC2. 
 
 
 
Figure 11. Graphical illustration explains the conclusion of paper 2.[272] 
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4.3 Paper 3 (manuscript) 
 
DNA methylation at intragenic CpG islands controls PRC2-mediated transcriptional 
regulation of MNX1 in Chronic lymphocytic leukemia 
This study is pertinent to paper 1 of this thesis, in the sense it is based on the global methylome 
data obtained from our previous study. The finding of paper 1 that there is a set of genes that are 
supposed to be upregulated by hypermethylation intrigued us to investigate other facet of the 
implication of methylation at intragenic CGIs in regulating gene expression in terms of the 
crosstalk with PRC2. In this regard, CLL cell lines were used as model system to dissect the 
interplay between DNA methylation and PRC2 within the intragenic context of the transcriptional 
unit upon global demethylation using DAC. Transcriptome analysis (RNA-seq) revealed that 35% 
of the differentially expressed genes are significantly downregulated in DAC-treated MEC1 cell 
lines compared to control counterparts. Molecular function analysis of this set of genes using GO 
terms for complete molecular function showed significant enrichment of DNA binding, 
transcriptional regulation and RNA polymerase II regulation and other relevant molecular 
processes. 
Of these genes,   Motor Neuron and Pancreas Homeobox (MNX1), which harbors high degree of 
methylation within gene body region according to MBD-seq data, was selected to follow the 
placement and function of PRC2 after removal of DNA methylation by DAC treatment (LogFC = 
-1.58; FDR= 4.10691690348078e-154). According to our recently published study, transcriptome 
analysis of CLL patients revealed a significant overexpression of MNX1 in CLL patients 
compared to normal cells from healthy donors.[282]Validation of MBD-seq[120] and RNA-
seq[282] was performed using an independent cohort of CLL patients (n = 20) and sorted normal 
B cells from healthy donors (n = 8) by Pyrosequencing and RT-PCR, respectively. Interestingly, 
intragenic methylation % at MNX1 gene body showed a significant positive correlation to relative 
expression of MNX1 (r = 0.472; p < 0.05) using the aforementioned independent CLL patient 
samples used for validation. 
The relationship between intragenic DNA methylation at MNX1 gene and PRC2 was then tested 
in CLL cell lines. Silencing of EZH2 in HG3 cell lines showed no significant effect on MNX1 
expression; nevertheless, this observation did not rule out the implication of PRC2 in regulating 
MNX1 expression. Notably, silencing EZH2 in HG3 cells that were maintained in DAC-
containing medium resulted in 45% in MNX1 expression compared to DAC-free maintained HG3 
cells (p < 0.005). In line with the downregulation of MNX1 expression upon DAC treatment, ChIP 
experiments revealed significant increase of the enrichment of both EZH2 and its prototypical 
mark H3K27me3 at promoter region and the intragenic region of MNX1 that was identified by 
MBD-seq analysis. This suggests that PRC2 in terms of occupancy and functionality of its 
catalytic subunit EZH2 is governed by the degree of intragenic CGIs methylation. Given that 
PRC2 has a preference towards locating unmethylated CGI, it is more likely that the relationship 
between intragenic CGIs methylation and PRC2 is adversarial. More tellingly, higher degrees of 
intragenic CGIs methylation might elicit a barrier that impede PRC2 binding to its target genomic 
loci, this was evidenced by the increase of EZH2 and H3K27me3 enrichment. Moreover the 
significant increase of MNX1 expression upon EZH2 silencing in HG3 growing in DAC-
supplemented medium, even though the effect of EZH2 silencing in control counterparts is 
insignificant supports the postulation that PRC2 is impeded by hypermethylation. Also, the 
significant increased enrichment of H3K27me1 after DAC treatment is suggested to be an 
intermediate product of PRC2 towards the ultimate trimethylation of H3K27 and point out to the 
processive mode of action of PRC2 that requires longer time for H3K27 trimethylation. Since 
monomethylation of H3K27 mark the bodies of actively transcribed genes [156, 157], H3K27me1 
is not an ad hoc product of PRC2 in this context, as the expression of MNX1 reduces upon DAC 
treatment. Furthermore, H3K36me3 enrichment across the gene body region that harbors 
hypermethylation showed no significant change upon DAC treatment; thus further support that 
H3K27me1 is an intermediate product of PRC2 matching the relatively short time if DAC 
treatment that covers only one doubling time of HG3 cells. Together, these results highlight the 
contextual mutual exclusivity of CGI methylation and PRC2, in the sense that PRC2 access to its 
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target genomic regions might be blocked by DNA methylation. This in part could be supported by 
the finding that most of the pluripotency-related genes that are pre-marked and silenced by PRC2 
in embryonic stem cells are prone to hypermethylation in cancer, a process that mirrors the 
unrestricted proliferation during pluripotency.[135]     
 
Conclusion:  
 
The results of this work address an adversarial relationship between intragenic CGIs methylation, 
and PRC2 and give an insight to non-canonical contribution of DNA methylation in 
transcriptional activation of MNX1 a putative oncogene. Herein, intragenic CGIs 
hypermethylation is found to render the expression of MNX1 high in CLL, by eliciting a barrier 
that impedes the access of EZH2 the catalytic subunit of PRC2 and thus protects its expression 
form the spread of the repressive mode of action of PRC2.  
 
 
 
 
 
Figure 12. Graphical illustration explains the conclusion of the manuscript 
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5 FUTURE PERSPECTIVES 
The post-sequencing era has witnessed a remarkable conceptual progress, which has in turn 
offered new insights on biological and physiological processes and has enriched understanding of 
the development and progression of diseases that jeopardize mankind. However, with the 
developments of efficient anticancer therapeutic strategies, still cancer represents a major threat to 
humankind all over the world. 
Aberrant epigenome has been proven to embrace the generation of the notorious cytogenetic 
lesions that expedite tumor progression and account for poor prognoses of several human cancers. 
The modalities of epigenetic machineries that control DNA methylation and histone modifications 
are highly influenced by contexts, in particular cancer-type contexts; thus entailing complete 
understanding of the aspects of epigenetic mechanisms including the non-canonical modalities. 
For instance, the deregulation of Polycomb proteins is differential among different cancers; loss-
of-function aberrations are documented in some malignancies, while gain-of-function are 
hallmarks of others. In addition, apart from mutations, EZH2 the catalytic core subunit of PRC2 
throughout the past decade has been shown to function non-canonically and independently of 
being a substantial part of PRC2. Studies on breast cancer subtypes, T-cell lymphoma and poor 
prognostic prostate cancer subset revealed that EZH2 functions in transcriptional activation of 
some genes of relevance to the corresponding cancer type/subtype. 
The development of therapeutic agents that target the PRC2-attributed HMT activity of EZH2 has 
proven high efficiency of treatment of several cancers and some of these agents have become in 
use for clinical trials. Nevertheless, these agents might not properly circumvent the HMT-
independent oncogenic modalities of EZH2 in some cancers. Accordingly, it is of an utmost 
importance to investigate the non-canonical behavior of EZH2 in Pan cancer-based studies and 
identify the target genes and their relevance to the respective malignancies. Moreover, the 
domains or subdomains of EZH2 protein have to be subject of intense interrogation in order to 
dissect the involvement of EZH2 in transcriptional activation, in terms of: 
• The domain(s) that contribute to enhancing gene expression of cancer-signature 
genes 
• The interface between such domain(s) of EZH2 with the transcriptional machinery, 
other chromatin-associated factors, and chromatin remodelers and how this 
influences the shift of mode of EZH2 from trans-repression towards trans-activation 
• How likely EZH2 assembles to or disassembles from the other core and non-core 
subunits of PRC2 genome-wide 
• The target genes in each cancer type/subtype, and how likely that EZH2 non-
canonically trans-activates universal oncogenes that generally contributes to cancer 
progression 
 
Comprehensive understanding of all the possible aspects of PRC2 deregulation and pinpointing its 
hitherto uncharacterized oncogenic facets would offer on the long-term a compendium of the 
different PRC2 modalities in different cancers and that would participate in paving the way for 
devising alternative therapeutic lines that specifically target the cancer type/subtype-attributed 
modality of PRC2 deregulation and thereby improve the clinical outcomes of cancer patients.  I 
would adopt such approach and line of research for my future career and I would consider 
investing the progressive advancement of CRISPR/Cas9 technologies, life cell imaging, 
proteomics, and bioinformatics along with high through-put based sequencing techniques for this 
short-term endeavor. 
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